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ABSTRACT OF THE DISSERTATION 
HUMAN PAPILLOMAVIRUS INFECTION AND VACCINATION POLICIES IN 
THE AMERICAN SOUTH  
by 
Dudith Pierre-Victor  
Florida International University, 2016 
Miami, Florida 
Professor Purnima Madhivanan, Major Professor 
In the United States, the South has a disproportionate burden of cervical cancer, 
yet research reporting regional prevalence of human papillomavirus (HPV) infection is 
scarce. Since 2008, Virginia has passed a HPV vaccine mandate and Louisiana a HPV 
education bill. This dissertation estimated the prevalence of HPV infection among 
females and assessed the impact of Virginia’s and Louisiana’s HPV vaccination policy on 
vaccination among adolescent females.   
The first manuscript estimated the prevalence of HPV infection using data from 
4,250 females collected during the 2007–2010 National Health and Nutrition 
Examination Survey.  Among 14–26 year-olds, the prevalence of high-risk oncogenic 
HPV was 25.6% (95% CI: 22.4  33.3) in the South and 29.1% (95% CI: 24.8  33.8) in the 
rest of the country (p= 0.15).  Among 27–59 year-olds, infection rates were 20.9% (95% 
CI: 17.4  24.9) for the South and 14.5% (95% CI: 12.9  16.3) for the rest of the country 
(p=0.0001). 
vi 

The second manuscript assessed the impact of Virginia’s HPV vaccine mandate 
on vaccination using National Immunization Survey-Teen 2008-2012 data (n=3,203). A 
difference-in-differences estimation and logistic regression analysis were performed with 
South Carolina and Tennessee serving as comparison states. Virginia’s mandate was not 
associated with an increase in vaccination rates.  Physician recommendation was strongly 
associated with vaccination in the Virginia-South Carolina (aOR=10.3; p=0.0001) and 
Virginia-Tennessee analyses (aOR=9.33; 95%CI: 6.11  14.3).     
The third manuscript assessed the impact of Louisiana’s HPV education policy on 
vaccination using difference-in-differences estimation and logistic regression analysis, 
with Alabama and Mississippi as comparison states (n=2,327). There was no evidence 
that the policy increased vaccination rates. Physician recommendation was associated 
with vaccination in the Louisiana-Alabama (aOR=7.74; 95% CI: 5.22  11.5) and 
Louisiana-Mississippi comparison (aOR=7.05; 95% CI: 4.6  10.5). 
This study found a higher prevalence of HPV infection among females aged 27  
59 years in the South compared to the rest of the country. Additionally, physician 
recommendation was strongly associated with vaccination despite HPV policy 
implementation. These findings highlight the importance of physician recommendation 
for HPV vaccination and the need for recommended cervical cancer screening, 
particularly in the South.   
 
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Introduction 
The southern region has long been known for its distinctiveness from the rest of 
the country, as evidenced in a letter written by Thomas Jefferson in 1785 (Savitt & 
Young, 1988). Several factors, including its unique Protestant Evangelical 
Fundamentalism, contributed to that distinctiveness. One of the most salient 
characteristics of the South is disease (Savitt & Young, 1988).  Malaria, yellow fever, 
typhoid fever, hookworm and pellagra were prevalent in the South compared to other 
United States regions (Savitt & Young, 1988). In the Colonial years, these diseases took a 
heavy toll on both poor white southerners as well as the large slave population on the 
plantations.  After the civil war, the South’s reputation for the poorest health in the nation 
suppressed immigration and investment thereby further delaying social and economic 
development (Savitt & Young, 1988).  In the 21st century, the South continues to 
maintain its distinctiveness. The proportion of individuals of Black/African descent in the 
region since the time of slavery, rurality, poor socioeconomic living conditions, and 
health disparities (Wimberley & Morris, 1996; Wimberly & Morris, 1997) being among 
the principal factors contributing to its distinctiveness.   
The South is comprised of 17 states: Delaware, District of Columbia, Florida, 
Georgia, Maryland, North Carolina, South Carolina, Virginia, West Virginia, Alabama, 
Kentucky, Mississippi Tennessee, Arkansas, Louisiana, Oklahoma and Texas (U.S. 
Census Bureau, 2013b).  A region of the South has also been identified as the Black Belt, 
which spans across 11 states (Wimberley & Morris, 1996; Wimberly & Morris, 1997). 
This particular region is comprised of counties with the percentage of African Americans 
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ranging from 18.5% to 26.7% (Wimberley & Morris, 1996; Wimberly & Morris, 1997). 
The Southern Black Belt is where Southern rurality, poor socio-economic conditions, and 
health disparities meet. When the distribution of most chronic diseases—such as 
cardiovascular diseases and diabetes—are mapped, the South or Sotheastern belt stands 
out, indicating higher prevalence than the rest of the country (Barker, Kirtland, Gregg, 
Geiss, & Thompson, 2011; Devesa et al., 1999; Lanska & Kuller, 1995).   
Cervical cancer is among the chronic conditions that disparately plague the South 
(Devesa et al., 1999; Howlader et al., 2013; U.S. Cancer Statistics Working Group, 
2015). In 2010, the top ten states with the highest incidence and mortality rates for 
cervical cancer were all located in the South (Howlader et al., 2013).  In 2012, the 
incidence of cervical cancer in the United States was 7.4 per 100,000 (U.S. Cancer 
Statistics Working Group, 2015). Only Maryland, Virginia, North and South Carolina 
had incidence rates below the national average. A similar geographic distribution is 
reported for cervical cancer mortality (U.S. Cancer Statistics Working Group, 2015).   
Human papillomavirus (HPV), the leading sexually transmitted infection (Cates, 
1999; Weinstock, Berman, & Cates, 2004), has been consistently linked to oropharyngeal 
and anogenital cancers (Bosch, Lorincz, Muñoz, Meijer, & Shah, 2002; Endo, Yamashita, 
Jin, Akutsu, & Jimbow, 2003; Gissmann & zur Hausen, 1980; Jones, Rowan, & Stewart, 
2005). The Food and Drug Administration had licensed the quadrivalent HPV vaccine 
(HPV4, Gardasil) in 2006, which protects against HPV 6,11,16, and 18 (Centers for 
Disease Control and Prevention, 2010b); the bivalent HPV vaccine (HPV2, Cervarix) in 
2009, which confers protection against HPV 16 and 18 (Centers for Disease Control and 
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Prevention, 2010a); and the nanovalent HPV vaccine (Gardasil9) in 2014, which confers 
protection against  HPV 6,11,16,18,31,33,45,52, and 58 (U.S. Food and Drug 
Administration, 2014). The HPV vaccine has a three-dose schedule recommended for 
boys and girls 11−12 years of age and catch-up vaccination for 13-26 year-olds (Centers 
for Disease Control and Prevention, 2013a). Currently, HPV vaccines are administered in 
primary health care settings (Herzog, Huh, & Einstein, 2010) including school-based 
health care centers (Lofink et al., 2013). 
Since the licensure of the vaccine, individual states have been enacting HPV 
vaccination policies to address funding for HPV education or  HPV vaccination (National 
Conference of State Legislatures, 2015). Several states have passed bills requiring HPV-
related education and HPV vaccine awareness for adolescents, parents, or both. Indiana, 
Utah, Iowa, New Jersey, and Washington took the lead on HPV and HPV vaccine 
awareness legislatures in the 2006  2007 period (National Conference of States 
Legislatures, 2015). Among Southern states, only the District of Columbia and Virginia 
had passed a HPV vaccine mandate for school-entry while North Carolina and Louisiana 
required that schools provide HPV vaccine education to parents of preteens and teens in 
specific grades (National Conference of State Legislatures, 2015). Virginia’s HPV 
vaccine mandate requires girls entering sixth grade to receive at least one dose of the 
HPV vaccine. Louisiana requires schools to provide HPV/HPV vaccine information to 
parents of adolescents in grades 6  12. Both policies were enacted in 2008 (National 
Conference of State Legislatures, 2015).   
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While HPV infection rates are available at the national level, there is a paucity of 
research that examines geographic variation in HPV infection prevalence. Women 
residing in the American South are disproportionately affected by cervical cancer.  
However, research studies estimating HPV infection prevalence and those examining 
socio-demographics and sexual behaviors associated with HPV infection are scarce. Such 
information is crucial to increase cervical cancer prevention in order to reduce cancer 
disparities.   
Despite the availability of HPV vaccine for the last nine years, vaccination rates 
are low among American adolescents (Centers for Diseases Control and Prevention, 
2013). Vaccination rates are particularly low in the Southern region, notwithstanding its 
high cervical cancer rates. In 2012, among 13-17 year-old females HPV vaccination rates 
were lower in the South (48.9%) compared to the Midwest (50.5%), the Northeast 
(58.2%), the West (61.4%), and the national average (53.8%) (Centers for Disease 
Control and Prevention, 2013b). Virginia’s HPV vaccine mandate for school-entry and 
Louisiana’s HPV vaccine awareness policies could serve as models for other Southern 
states if they are effective. While several states have introduced similar HPV vaccine 
awareness policies and HPV vaccine mandate for school-entry (National Conference of 
State Legislatures, 2015), these policies have not been evaluated.  
In light of cervical cancer disparities in the Southern region, the impact evaluation 
of Virginia’s HPV vaccine mandate as a school-entry requirement and Louisiana’s HPV 
vaccine education policies requiring HPV and HPV vaccine education for parents and 
students is crucial.  To contribute to this body of literature, the first manuscript estimated 
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the prevalence of HPV infection in Southern region compared to the rest of the country. 
Findings will shed light on the burden of HPV infection in the region in addition to 
highlighting HPV infection disparities. Such information can guide national cervical 
cancer prevention efforts to allocate limited resources to areas with greater needs. The 
second manuscript assessed the impact of Virginia’s HPV vaccine mandate as a school-
entry requirement for girls in the sixth grade on HPV vaccination among 13  17 year-old 
females. The third manuscript assessed the impact of Louisiana’s law requiring HPV and 
HPV vaccine education for parents and students on HPV vaccination among 13  17 year-
old females. HPV vaccine mandate for school-entry and HPV education legislature have 
been introduced in several states (National Conference of State Legislatures, 2015). 
Consequently, the impact assessment of both policies will shed light on whether parental 
HPV awareness or HPV vaccine mandate for school-entry is effective to increase HPV 
vaccination. Together, the second and the third manuscripts will provide policy-makers 
with information that can assist them in deciding the best HPV vaccination policies. 
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Manuscript 1 
Human Papillomavirus Infections in the American South and Other United States 
Regions 
Abstract 
Human papillomavirus (HPV) infection is the most common sexually transmitted 
infection worldwide and has been linked to several cancers, including cervical cancer. In 
the United States, the Southern region has a disproportionate burden of cervical cancer, 
and research about the epidemiology of HPV in the region is scarce. This study estimates 
the prevalence and correlates of HPV infections among 14–59 year-old females.   
Data from 4,250 females aged 14–59 years collected during the 2007–2010 
National Health and Nutrition Examination Survey were used. The prevalence of HPV 
infection was estimated for the South, Northeast, Midwest, and West combined.  
Weighted chi-square test and logistic regression were performed to examine the 
association between HPV infection and socio- and behavioral demographics.   
Among 14–26 year-old females, the prevalence of high-risk oncogenic HPV types 
was 25.6% (95% confidence (CI): 22.4  33.3) in the South and 29.1% (95% CI: 24.8  
33.8) in the other regions (p= 0.15). Among 27–59 year-old women, infection with high-
risk oncogenic types was 20.9% (95% CI: 17.4  24.9) in the South compared to 14.5% 
(95% CI: 12.9  16.3) in other regions (p=0.0001).  
This study found a higher prevalence of infection from high-risk oncogenic types 
among 27  59 year-olds. These findings indicate the importance of promoting HPV 
vaccination as well as cervical cancer screening, particularly in the Southern region of the 
United States.   
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Background 
Human papillomavirus (HPV) is the most common sexually transmitted infection 
(STI) worldwide and has been consistently linked to head, neck, pharyngeal, and 
anogenital cancers (Forman et al., 2012). Over 100 HPV types infect humans, with 40 of 
these HPV types infecting mainly the anogenital tract (Franco, Duarte-Franco, & 
Ferenczy, 2001). Most HPV-related cancers result from infections from HPV types 16 
and 18 (Muñoz et al., 2003). According to their association with pre-malignancy and 
invasive cancer, HPV types are classified as high- or low-risk oncogenic, and non-
oncogenic (Bosch et al., 2002; Franco et al., 2001; Wright, Denny, & Kuhn, 2000).  
Cervical cancer is the fourth most common cancer worldwide and 
disproportionately affects women in developing and underdeveloped countries. Among 
HPV-related cancers, cervical cancer is the most prevalent. In developed countries, 
cervical cancer affects poor and disadvantaged women (International Agency for 
Research on Cancer, 2014). In the United States, cervical cancer mainly affects 
disadvantaged, poor women with limited access to healthcare such as those living in the 
Appalachian (Devesa et al., 1999; Horner et al., 2011), and the Southern regions (Devesa 
et al., 1999). In 2010, the national cervical cancer incidence was 7.6 per 100,000. The 
seven states with the highest cervical cancer incidence rates were all located in the South: 
West Virginia (11.6 per 100,000), Arkansas (10.7), Oklahoma (10.3), Mississippi (10.2), 
Washington D.C. (9.7), Texas (9.4), and Louisiana (9.1) (Howlader et al., 2013).  
Women residing in the American South are disproportionately affected by 
cervical cancer. However, research studies estimating prevalence of HPV infection and 
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associated socio-demographic characteristics and sexual behaviors are lacking in the 
region. Such information is crucial to increase HPV vaccination and cervical cancer 
screening in order to reduce cancer disparities. The present study estimates the 
prevalence of HPV infection from high-risk oncogenic, any oncogenic, and non-
oncogenic types and examines the correlates of HPV infections in the American South.  
We hypothesized that the rates of infection from high-risk HPV types would be higher in 
the South than in the rest of the United States.   
Methods 
Study Design and Population  
The National Health and Nutrition Examination Survey (NHANES) data are 
collected through a multifaceted probability sampling strategy in order to obtain a 
representative sample of the noninstitutionalized population in the United States (Curtin, 
Lester et al., 2013). NHANES detailed methodologies have been published elsewhere 
(Curtin, Lester et al., 2013; Zipf et al., 2013). NHANES data collection occurs in two 
stages: a home interview and a health examination. Upon selection, participants are first 
screened to ensure eligibility. Eligible participants complete the home interview and are 
invited to the Mobile Exam Center (MEC) for computer-assisted personal interview 
(CAPI) questionnaires, audio computer-assisted personal self-interview (ACASI) 
questionnaires, examinations, and biological specimen collection (Zipf et al., 2013).  
From 2003 to 2010, females 14  59 years are asked to self-collect vaginal 
samples. Several studies have found self-collected vaginal swabs to be slightly less or as 
sensitive as physician-collected samples (Bhatla et al., 2009; Ogoina, Musa, & 
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Onyemelukwe, 2013; Petignat et al., 2007; Zhao et al., 2012). A systematic review 
comparing self-collected and physician-collected samples for low- and high-risk types 
HPV DNA detection from 18 studies estimated the average detection rate at 27.4% (26.2-
28.6) for self-sampling and 28.0% (26.8-29.1) for physician-sampling (Petignat et al., 
2007). NHANES reports HPV test results as positive, negative, inadequate or missing for 
40 HPV types.   
Two NHANES survey cycles, 2007  2008 and 2009  2010, were combined to 
maximize the sample for the analysis.  A total of 4,250 females aged 14  59 years 
provided adequate self-collected vaginal samples for HPV DNA detection from 2007 to 
2010. Based on HPV vaccine eligibility, the sample was divided into those still eligible 
for HPV vaccine (14  26 years) and those no longer eligible for HPV vaccine (27  59 
years).    
Variables 
HPV infection status was the outcome of interest. Following the classification 
scheme developed by several researchers (Bosch et al., 2002; Bouvard et al., 2009; 
Franco et al., 2001), HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59 were 
classified as high-risk oncogenic types. HPV types 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 
45, 51, 52, 53, 55, 56, 58, and 59 were classified as oncogenic types. The remaining HPV 
types were classified as non-oncogenic.  
Socio-demographic variables from the home interview survey, sexual behavior 
variables from the ACASI questionnaires, reproductive health variables from the CAPI 
questionnaires, and HPV infection status from the laboratory data were merged for the 
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analysis. HPV infection status, race/ethnicity, country of birth, country of citizenship, 
federal poverty level, health insurance status, healthcare utilization variables, HPV 
infection status, use of contraception, duration of contraception use, age at first sexual 
intercourse, and number of lifetime partners were included in the analysis. Females who 
tested positive for at least one of the high-risk oncogenic types were classified as being 
infected from high-risk oncogenic HPV types. The same criterion was used for any 
oncogenic types. Since the region and state of residence are restricted variables, the 
dataset was accessed and analyzed at the Restricted Data Center (Atlanta, GA).  
Furthermore, to prevent potential disclosure, the region rather than the state of residence 
of survey respondents was specified in the dataset.   
Statistical Analysis 
STATA svy (StataCorp, 2013) commands were used to conduct the analyses to 
account for the complex multistage study design and sample weight. Since two survey 
cycles were combined, NHANES guidelines were followed to compute the new MEC 
sample weight used in the analysis. Women 14  59 years of age from all racial/ethnic 
groups were included in the analysis. The proportion of respondents who tested positive 
for high-risk oncogenic, any oncogenic, and non-oncogenic HPV types for 2007  2010 
were computed for the South separately and the three other regions combined (Northeast, 
Midwest, and West). A 95% confidence interval was computed for each proportion. 
Weighted chi-square analyses were performed to examine the association between HPV 
infection and important demographic, healthcare utilization, and sexual behavior 
variables. Variables that were significantly associated with HPV infection from high-risk 
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oncogenic and any oncogenic type HPV and sexual behavior variables were included in a 
multivariable logistic regression to identify factors independently associated with HPV 
infection among sexually active women. We performed analysis with all females for 
whom the variables of interest were present. A 5% significance level was used for all 
analyses.  
Results 
HPV Prevalence 
14–26 year-old females 
The prevalence of high-risk oncogenic types was 25.6% (95% CI: 22.4  33.3) in 
the South and 29.1% (95% CI: 24.8  33.8) in the rest of the U.S. (p=0.15). The 
prevalence of any oncogenic type was 31.7% (95% CI: 26.4  37.6) in the South and 
32.3% (95% CI: 27.9  36.9) in other regions (p=0.84). Non-oncogenic type prevalence 
was 36.5% (95% CI: 30.0  43.4) in the South and 31.9% (95% CI: 26.9  37.4) in the other 
regions (p=0.08) (Table 1).   
27-59 year-old women 
Infection with high-risk oncogenic types was 20.9% (95% CI: 17.4  24.9) in the 
South compared to 14.5% (95% CI: 12.9  16.3) in other regions (p=0.0001).  For 
infection from any oncogenic types, infection rates were 24.0% (95% CI: 19.9  28.7) and 
17.9% (95% CI: 16.3  19.5) for the South and other regions respectively (p=0.0001) 
(Table 1).   
[Table 1 Here] 
14 
 
Demographics Associated with HPV Infection  
14–26 year-old females 
In the South, infection from high-risk oncogenic type HPV varied significantly by 
race/ethnicity, history of contraceptive use, sexual activity status, and number of lifetime 
sex partners (Table 2). Among women living in the rest of the country, infection with 
high-risk oncogenic types differed by marital status, poverty index, insurance status, 
history of contraceptive use, sexual activity status, number of lifetime sex partners, and 
having had at least one sex partner five years older (Table 2). In the South, infection from 
any oncogenic types varied by race/ethnicity, history of contraceptive use, sexual activity 
status, and number of lifetime sex partners (Table 3). In the rest of the country, infection 
from any oncogenic types varied by marital status, insurance status, history of 
contraceptive use, sexual activity status, and number of lifetime sex partners (Table 3). 
[Table 2 Here] 
[Table 3 Here] 
27–59 year-old women 
In the Southern region, infection from high-risk oncogenic HPV types varied 
significantly by race/ethnicity, country of birth, marital status, poverty index, insurance 
status, and number of lifetime sex partners (Table 4). Among women living in other US 
regions, infection from high-risk oncogenic types differed by race/ethnicity, marital 
status, poverty index, insurance status, type of place one receives care, healthcare 
utilization, age at first sexual intercourse, number of sex partners 5 years or older, and 
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number of lifetime sex partners (Table 4). For the Southern region, infection from any 
oncogenic types varied by race/ethnicity, country of birth, marital status, poverty index, 
insurance status, and number of lifetime sex partners (Table 5). In the rest of the country, 
infection from any oncogenic types differed by race/ethnicity, marital status, poverty 
index, type of place respondents receive care, age at first sexual intercourse, number of 
lifetime sex partners, and having had at least one sex partner five years older (Table 5). 
[Table 4 Here] 
[Table 5 Here] 
Correlates of HPV Infection among Sexually Active Women 
14–26 year-old females 
Among 14–26 year-old females in the South, those whose income was 300–499% 
above the federal poverty level had lower odds of infection from high-risk HPV 
oncogenic types compared to those whose income was below the federal poverty level 
(adjusted odds ratio (aOR)= 0.36; p< 0.01). Additionally, females who had four or more 
lifetime sex partners had greater odds of infection with high-risk oncogenic types 
compared to those who had three or fewer sex partners (aOR= 8.27; p<0.001) (Table 6).  
Among 14–26 year-old females living in other regions, those who have never been 
married had greater odds to be infected from high-risk oncogenic types compared to 
those who were married (aOR= 12.79; p<0.001), and those who were divorced or 
separated had higher odds of infection (aOR= 6.09; p<0.001) (Table 6).     
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For infection with any oncogenic types in the South, females whose income was 
200–499% above the poverty index had lower odds of infection compared to those whose 
income was below the poverty index (aOR= 0.45; p<0.05) (Table 6). Southern females 
who had insurance coverage had higher odds of infection compared to those who had no 
coverage (aOR=2.48; p<0.01). Those who had four or more sex partners had higher odds 
of infection compared to those who had three or fewer partners (aOR=8.51; p<0.001).  
Among females in other regions, those who had never been married had greater odds to 
be infected with high-risk oncogenic types compared to those who were married (aOR= 
14.1; p<0.001), and those who were divorced or separated had higher odds of infection 
(aOR= 6.13; p<0.001). Additionally, females who had four or more sex partners had 
higher odds of infection compared to those who had three or fewer sex partners 
(aOR=4.40; p<0.001) (Table 6).     
 [Table 6 Here] 
27–59 year-old females 
Among 27–59 year-old women in the South, those who had never been married 
had increased odds to be infected with high-risk oncogenic types (aOR= 5.14; p<0.01), 
and the odds were also higher for those who were no longer married (aOR=2.98; p<0.05) 
compared to married women (Table 7). In the other regions, women who had never been 
married (aOR= 2.38; p<0.01) and those who were previously married (aOR= 4.26; 
p<0.05) had higher odds of infection from high-risk oncogenic types. Women with 
household income 300–499% above the poverty index had lower odds to be infected 
(aOR= 0.26; p<0.01). Additionally, women who had one or more sex partners at least 
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five years older (aOR= 1.82; p<0.01) and who had four or more sex partners (aOR= 3.78; 
p<0.01) had greater odds to be infected (Table 7). 
For any oncogenic types, in the South, women who had never been married had 
higher odds of infection (aOR= 4.27; p<0.01). In the rest of the country, women who had 
never been married had greater odds to be infected (aOR= 2.20; p<0.01) and those who 
were divorced, separated, or widowed also had increased odds to be infected (aOR= 4.16; 
p<0.01). Women whose income was 300–499% above the poverty index had lower odds 
of infection from any oncogenic types (aOR= 0.46; p<0.01). Those who had four or more 
sex partners had higher odds of infection (aOR= 3.90; p<0.001), and those who had their 
sexual debut at 15 years or older had lower odds to be infected from any oncogenic types 
compared those who had their sexual debut at 14 years or younger (aOR= 0.47; p<0.01) 
(Table 7).  
[Table 7 Here] 
Discussion 
Cervical cancer is more prevalent in the Southern region compared to the rest of 
the United States, and this study found that the prevalence of HPV infections from high-
risk oncogenic types was higher in the South than the rest of the United States, among 
women aged 27  59 years but not among those 14  26 years old. Among 14  26 year-old 
females, having four or more lifetime sex partners was positively associated with 
infection from high-risk and any oncogenic types infection in the South and the rest of 
the country.  Among 27  59 year-old females, having four or more lifetime sex partners 
was positively associated with infection from high-risk and any oncogenic types infection 
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in the rest of the country but not in the South. Moreover, sexually active women who 
have never been married and those who were divorced, separated, or widowed to have a 
greater odds of infection from any oncogenic and high-risk oncogenic types. 
The prevalence of infection from high-risk oncogenic types was higher in the 
South compared to the rest of the U.S. among 27  59 year-old females.  Although there is 
limited literature investigating geographic variation in HPV infection, a study estimated 
HPV prevalence among women in the Appalachia, a region with high rates of cervical 
cancer and predominantly non-Hispanic White population (Reiter, Katz, Ruffin, et al., 
2013). The study found higher prevalence of high-risk infection among Appalachian 
women (Reiter, Katz, Ruffin, et al., 2013) when compared to the national estimates for 
non-Hispanic White females (Hariri et al., 2011). The majority of the Appalachian 
women were between the ages of 18 and 40 years (Reiter, Katz, Ruffin, et al., 2013).  The 
difference in the prevalence of infection from high-risk oncogenic types in the South 
compared to the rest of the U.S. among 27  59 year-old females appears to be smaller 
than the difference in cervical cancer incidence and mortality. Therefore, this difference 
in the prevalence is not large enough to account for the higher prevalence of cervical 
cancer in the South.   
Among 14  26 year-olds, the prevalence of infection from high-risk oncogenic or 
any oncogenic types HPV was not higher in the South compared to the rest of the 
country.  Using the 2003  2006 and the 2007  2010 NHANES survey cycles, a study 
investigated the change in the prevalence of infection from HPV types 6, 11, 16, or 18 
(Markowitz et al., 2013).  Among females aged 14  19 years, HPV infection prevalence 
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declined from 11.5% in the 2003  2006 cycle to 5.1% in the 2007  2010 cycle. Similar 
decline was not observed in the older age-groups (Markowitz et al., 2013).  Comparable 
rates of infection from high-risk or any oncogenic types between the South and the rest of 
the country among 14  26 year-olds are probably due to the national decline in HPV 
infection in the vaccine-eligible age-group.   
Among 14  26 year-old females, this study found that having four or more 
lifetime sex partners was positively associated with infection from high-risk and any 
oncogenic types in the South and the rest of the country.  However, among 27  59 year-
old females, having four or more lifetime sex partners was positively associated with 
infection from high-risk and any oncogenic types in the rest of the country but not in the 
South. Previous research has reported that increasing number of lifetime sex partners was 
associated with HPV infection (Dunne et al., 2007; Markowitz et al., 2009; Reiter, Katz, 
Ruffin, et al., 2013).  It is not clear as to why increasing number of sex partners was not 
associated with infection from high-risk or oncogenic types in the South. 
The present study also found sexually active women who had never been married 
and those who were divorced, separated, or widowed had greater odds of infection from 
any oncogenic and high-risk oncogenic types. Several studies have reported higher 
prevalence of HPV infection among unmarried women (Dunne et al., 2007; Kahn et al., 
2007; Reiter, Katz, Ruffin, et al., 2013).  The absence of a long-term and committed sex 
partner facilitates multiple sexual partnerships or short-term sexual partnerships, which 
increase the risk of HPV infection. This may help explain the higher prevalence of 
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infection from high-risk and any oncogenic types observed among unmarried sexually 
active women.   
The results indicated that the prevalence of infection from high-risk oncogenic 
types was higher in the South compared to the rest of the U.S. among 27  59 year-old 
females. Public health efforts to increase cervical cancer screening in the South as well as 
efforts to increase HPV vaccination among vaccine-eligible females must continue in 
order to decrease the disparities in cervical cancer mortality. Healthy People 2020’s goal 
is to increase the proportion of 21–65 year-old women who receive a cervical cancer 
screening based on the most recent guidelines to 93% (U.S. Department of Health and 
Human Services, 2014). In 2013, 78.5% of women aged 21  65 years had a pap smear test 
in the past three years (National Institute of Health, 2015). This report found lower 
cervical cancer screening rates among women living 200% or below the poverty index 
and among women who had less than high school education (National Institute of Health, 
2015). Doescher and colleagues reported that women with low socio-economic status, 
particularly those residing in rural areas, were less likely to be screened for cervical 
cancer (Doescher & Jackson, 2009). Thus, Southern women of low socio-economic 
status, especially those living in rural areas, should be targeted for cervical cancer 
screening.   
The present study had several limitations. First, sexual behaviors were self-
reported, which inevitably lends to poor recall and social desirability bias. Sexual 
behavior is generally considered a private and sensitive matter. As a result, most 
individuals are not enthusiastic about revealing their sexual practices due to social 
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stigma, embarrassment, or loss of confidentiality (Brener, Billy, & Grady, 2003; Kelly, 
Soler-Hampejsek, Mensch, & Hewett, 2013; O’Sullivan, 2008). Consequently, such 
behaviors may be underrepresented.  In the same vein, previous research has reported that 
responses to ACASI collecting sexual behavior data are generally more accurate 
compared to face-to-face interviews (Ghanem, Hutton, Zenilman, Zimba, & Erbelding, 
2005; Phillips, Gomez, Boily, & Garnett, 2010).  NHANES collects sexual behavior data 
using ACASI thereby reducing social desirability bias in this study. Moreover, the 
vaginal swabs were self-collected, and HPV testing could not be performed for some 
respondents due to inadequate specimen collection. However, this study also had several 
strengths.  First, the study used a nationally representative sample which is robust against 
selection bias.  Additionally, NHANES accounts for participant non-response.  As a 
result, these aspects lends to more reliable and valid findings. Moreover, the present 
study is among the few to have attempted to assess the prevalence of infections from high 
and low-risk HPV among 14  59 year-old women in a region with a disparate cervical 
cancer burden.   
Conclusion 
This study estimated the prevalence of infection among females for the South and 
the rest of the country and found a higher prevalence of infection from high-risk 
oncogenic and any oncogenic HPV types among 27  59 year-old Southern females 
compared to the rest of the country, but not among the 14  26 year-olds. Women in the 
Southern region remain at higher risk of developing and dying from cervical cancer, and 
the higher prevalence of infection from high-risk oncogenic and any oncogenic HPV 
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types among 27  59 year-olds in the South partially explains the higher prevalence of 
cervical cancer in the South.  However, the difference in HPV prevalence in the older 
age-group seems to be smaller than the difference in cancer incidence between the South 
and other regions. This suggests that the disparities in cervical cancer incidence are not 
only being driven by the differences in the epidemiology of HPV alone, but also by 
disparities in cervical cancer screening. Efforts to make cervical cancer screening 
accessible to disadvantaged women in the region must continue in order to reduce 
disparities in cervical cancer mortality.   
Among 14  26 year-olds, the prevalence of infection from high-risk oncogenic 
and any oncogenic types HPV was relatively high in the South and the rest of the 
country.  These findings reiterate the need for HPV vaccination to be administered to pre-
teens, prior to their sexual debut. Additionally, females aged 14  26 years are still eligible 
for HPV vaccination catch-up. Consequently, healthcare providers should recommend the 
vaccine to 14  26 year-old females even if they are already infected with one HPV type as 
they can be protected from other HPV types covered by the vaccine. 
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Tables 
Table 1. Prevalence of high-risk oncogenic, oncogenic, and non-oncogenic types 
HPV  
14-26 year-old females Regiona p-value 
South (n=532) Otherb  (n=811) 
High-risk oncogenicc types infection   0.15 
Yes 25.6 (22.4-33.3) 29.1 (24.8-33.8)  
No 74.4 (66.7-77.5) 70.9 (66.2-75.2)  
Any oncogenicd types infection   0.84 
Yes 31.7 (26.4-37.6) 32.3 (27.9-36.9)  
No 68.3 (62.4-73.6) 67.7 (63.0-72.1)  
Non-oncogenice types infection   0.08 
Yes 36.5 (30.0-43.4) 31.9 (26.9-37.4)  
No 63.4 (56.6-69.9) 68.1 (62.6-73.1)  
27-59 year-old females South (n=1,066) Other b (n=1841)  
26 
 
High-risk oncogenicc types infection   0.0001 
Yes 20.9 (17.4-24.9) 14.5 (12.9-16.3)  
No 79.1 (75.1-82.6) 85.5 (83.7-87.1)  
Any oncogenicd types infection   0.0001 
Yes 24.0 (19.9-28.7) 17.9 (16.3-19.5)  
No 76.0 (71.3-80.1) 82.1 (80.5-83.7)  
Non-oncogenice types infection   0.014 
Yes 32.4 (29.6-35.4) 28.1 (26.3-30.1)  
No 67.6 (64.6-70.4) 71.9 (69.9-73.7)  
aTo prevent potential disclosure, the region rather than the state of residence was included 
in the dataset 
bNortheast, West, and Midwest combined 
cHPV  types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
dHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
eAll other HPV types 
 
 
Table 2. Socio-demographic and behavioral characteristics associated with infection 
from high-risk types among 14-26 year-old females 
 HR Oncogenica types 
Characteristicsa South (n= 532 ) Otherb regions (n=811) 
Infection 
Status 
p-value Infection 
Status 
p-value 
Yes No Yes No  
Race/Ethnicity % % 0.04 %  %  0.2 
Non-Hispanic White 44.2 55.7  65.6 63.0  
Non-Hispanic Black 34.2 19.0  11.4 8.9  
Other  21.6 25.3  23.0 28.1  
Country of birth 
 
 0.28   0.7 
US 89.9 88.0  86.5 88.4  
Other 10.1 12.0  13.5 11.6  
Country of citizenship 
 
 0.58   0.9 
US 93.8 92.0  91.7 91.6  
Other 6.2 7.4  8.3 8.4  
Marital Status 
 
 0.5   0.00001 
Married 22.5 31.3  4.8 25.2  
Never married 2  65.3 65.3  69.3 53.2  
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Divorced/separated/cohabitating 12.2 13.1  25.9 21.6  
Income to federal poverty level 
 
 0.45   0.03 
<100% 35.6 25.2  26.1 24.4  
100-299% 22.8 25.5  23.6 20.1  
300-499% 27.4 30.8  29.1 24.4  
 500%  14.2 18.5  21.2 31.1  
Health insurance 
 
 0.55   0.036 
Yes  69.1 74.3  68.3 79.3  
No 30.9 25.7  31.7 20.7  
Type of place most often go for 
healthcare 
 
 0.39   0.7 
Doctor's office 60.3 66.9  74.0 71.8  
Other 39.7 33.1  26.0 28.2  
No. of times receive healthcare 
last year 
 
 0.69   0.8 
None 10.4 13.2  12.2 10.8  
3  57.2 52.2  50.1 52.2  
4 32.4 34.6  37.7 37.0  
Ever taken birth control pills 
 
 0.005   0.0001 
Yes 70.2 45.6  62.2 42.5  
No 29.8 54.4  37.8 57.5  
No. of years of birth control 
pills 
 
 0.51   0.5 
<2 43.2 47.6  44.4 50.8  
2 56.8 52.4  55.6 49.2  
Ever had sexe    
 
 0.00001   0.00001 
Yes 95.5 67.1  95.0 62.7  
No 4.5 32.9  5.0 37.3  
Age at first sexual intercourse 
 
 0.96   0.6 
9-14 years 23.8 23.9  25.5 22.4  
>= 15 years  76.2 76.1  74.5 77.6  
No. of lifetime sex partners  
 
 0.00001   0.00001 
3 20.5 66.3  27.3 64.7  
4 79.5 33.7  72.7 35.3  
No. of sex partners 5+ years 
older  
 
 0.52   0.002 
None 71.1 75.8  59.0 75.9  
1 28.9 24.2  41.0 24.1  
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aHPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
bNortheast, West, and Midwest combined 
aHPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
bHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
cNortheast, West, and Midwest combined 
 
Table 3. Socio-demographic and behavioral characteristics associated with infection 
from any oncogenic types among 14-26 year-old females 
 Any oncogenica HPV types 
Characteristicsa South (n= 532 ) Otherb regions (n=811) 
Infection 
Status 
p-value Infection 
Status 
p-value 
Yes No Yes No 
Race/Ethnicity %  %  0.015 %  %  0.14 
Non-Hispanic White 43.6 56.7  65.6 62.8  
Non-Hispanic Black 34.4 18.0  11.7 8.7  
Other  22.0 25.3  22.7 28.5  
Country of birth 
 
 0.15   0.8 
US 90.8 87.4  87.4 88.0  
Other 9.2 12.8  12.6 12.0  
Country of citizenship 
 
    0.6 
US 94.4 92.2 0.35 92.3 91.3  
Other 5.6 7.8  7.7 8.7  
Marital Status 
 
 0.5   0.00001 
Married 23.4 31.6  5.1 26.7  
Never married 64.2 55.3  69.4 51.7  
Divorced/separated/cohabitating 12.4 13.1  25.5 21.6  
Income to federal poverty level 
 
 0.3   0.3 
<100% 36.2 24.3  26.6 24.0  
100-299% 21.9 26.1  23.8 19.8  
300-499% 29.6 29.9  27.5 25.0  
 500%  12.3 19.7  22.1 31.2  
Health insurance 
 
 0.6   0.02 
Yes  70.3   67.6 80.2  
No 29.7 74.0  32.4 19.8  
Type of place most often go for 
healthcare 
 
26.0 0.13   0.8 
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Doctor's office 56.6 69.0  71.6 72.8  
Other 43.4 31.0  28.4 27.2  
No. of times receive healthcare 
last year  
 
 0.92   0.5 
None 11.9 12.7  12.9 10.3  
3  54.7 53.1  48.8 53.0  
4 33.4 34.2  38.3 36.7  
Ever taken birth control pills 
 
 0.0005   0.0001 
Yes 69.8 44.4  63.3 41.2  
No 30.2 55.6  36.7 58.8  
No. of years of birth control 
pills 
 
 0.11   0.8 
<2 41.8 48.9  44.2 51.4  
2 58.2 51.1  55.8 48.6  
Ever had sexe    
 
 0.00001   0.00001 
Yes 95.2 65.7  95.4 61.2  
No 4.8 34.3  4.6 38.8  
Age at first sexual intercourse 
 
 0.8   0.5 
9-14 years 23.1 24.3  25.4 22.2  
>= 15 years  76.9 75.7  74.6 77.8  
No. of lifetime sex partners  
 
 0.00001   0.00001 
3 22.0 68.9  27.0 67.0  
4 78.0 31.1  73.0 33.0  
No. of sex partners 5+ years 
older  
 
 0.08   0.001 
None 68.3 78.1  59.2 76.9  
1 31.7 21.9  40.8 23.1  
aHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
bNortheast, West, and Midwest combined 
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Table 4.  Socio-demographic and behavioral characteristics associated with infection 
from high-risk oncogenic types among 27-59 year-old females 
 HR Oncogenica types 
Characteristics South (n= 1,066 ) Other regions (n=1841) 
Infection 
Status 
p-value Infection 
Status 
p-value 
Yes No  Yes No 
Race/Ethnicity %  %  0.017 % % 0.004 
Non-Hispanic White 57.9 59.0  64.8 73.1  
Non-Hispanic Black 26.1 18.9  13.8 7.3  
Other  16.0 22.1  21.5 19.6  
Country of birth 
 
 0.04   0.9 
US 91.0 83.2  82.4 82.1  
Other 9.0 16.8  17.6 17.9  
Country of citizenship 
 
 0.06   0.6 
US 93.5 90.6  91.3 90.2  
Other 6.5 9.4  8.7 9.2  
Marital Status 
 
 0.0000
1 
 
 0.00001 
Married 38.1 66.6  36.1 65.9  
Never married  18.4 8.9  20.3 11.4  
Divorced/separated/cohabitati
ng 
43.5 24.5  43.6 22.7  
Income to federal poverty 
level 
 
 0.008   0.0002 
<100% 27.9 16.8  21.9 10.9  
100-299% 22.3 21.5  22.1 16.6  
300-499% 27.7 26.8  19.9 28.9  
 500%  22.1 34.9  36.1 43.6  
Health insurance 
 
 0.006   0.02 
Yes  64.2 76.9  79.2 85.6  
No 35.8 23.1  20.8 14.4  
Type of place most often go 
for healthcare  
 
 0.7   0.01 
Doctor's office 76.1 77.5  71.0 77.3  
Other 23.9 22.5  29.0 22.7  
No. of healthcare visits last 
year 
 
 0.5   0.041 
None 14.9 12.0  13.3 12.0  
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3  47.8 48.8  55.5 48.5  
4 37.3 39.2  31.2 39.5  
Ever taken birth control pills 
 
 0.97   0.43 
Yes 83.7 83.6  84.8 82.8  
No 16.3 16.4  15.2 17.2  
No. of years of birth control 
pills 
 
 0.15   0.04 
<2 30.6 25.0  34.1 25.2  
2 69.4 75.0  65.9 74.8  
Ever had sexe    
 
 0.15   0.14 
Yes 98.2 98.3  98.8 97.7  
No 1.8 1.8  1.2 2.3  
Age at first sexual intercourse 
 
 0.47   0.016 
9-14 years 17.3 13.9  14.1 9.9  
>= 15 years  82.7 86.1  85.9 90.1  
No. of lifetime sex partners  
 
 0.0004   0.00001 
3 21.8 38.7  20.3 41.4  
4 78.2 61.3  79.7 58.6  
No. of sex partners 5+ years 
older  
 
 0.17   0.0002 
None 58.1 72.7  58.4 75.2  
1 41.9 27.3  41.6 24.8  
aHPV types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
bNortheast, West, and Midwest combined 
 
Table 5.  Socio-demographic and behavioral characteristics associated with infection 
from any oncogenic types among 27-59 year-old females 
 Any oncogenica HPV types HPV 
Characteristics South (n=1,066) Otherb regions (n= 1,841) 
Infection 
Status 
p-value Infection 
Status 
p-value 
Yes No Yes No 
Race/Ethnicity %  %  0.02 %  %  0.015 
Non-Hispanic White 56.9 59.4  66.4 73.1  
Non-Hispanic Black 25.9 18.6  12.5 7.3  
Other  17.2 22.0  21.2 19.6  
Country of birth 
 
 0.02   0.7 
US 90.8 82.9  83.7 81.9  
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Other 9.2 17.1  16.3 18.1  
Country of citizenship 
 
 0.15   0.32 
US 93.3 90.5  92.0 90.0  
Other 6.7 9.5  8.0 10.0  
Marital Status 
 
 0.0000
1 
 
 0.00001 
Married 39.6 67.4  40.1 66.2  
Never married  18.1 8.6  17.4 11.7  
Divorced/separated/cohabitati
ng 
42.3 24.0  42.4 22.1  
Income to federal poverty 
level 
 
 0.006   0.001 
<100% 27.2 16.5  20.0 10.9  
100-299% 23.3 21.2  21.3 16.5  
300-499% 28.1 26.6  21.3 29.0  
 500%  21.4 35.6  37.4 43.6  
Health insurance 
 
 0.004   0.05 
Yes  64.0 77.5  80.8 85.5  
No 36.0 22.5  19.2 14.5  
Type of place most often go 
for healthcare  
 
 0.4   0.01 
Doctor's office 74.8 77.9  71.6 77.5  
Other 25.2 22.1  28.4 22.5  
No. of healthcare visits last 
year 
 
 0.8   0.4 
None 13.6 12.3  12.4 12.2  
3  48.5 48.6  52.9 48.7  
4 37.9 39.1  34.8 39.1  
Ever taken birth control pills 
 
 0.9   0.9 
Yes 83.2 83.7  83.3 83.1  
No 16.8 16.3  16.7 16.9  
No. of years of birth control 
pills 
 
 0.2   0.08 
<2 30.4 24.9  32.6 25.2  
2 69.6 75.1  67.4 74.8  
Ever had sexe    
 
 0.5   0.2 
Yes 97.9 97.4  98.6 97.7  
No 2.1 2.6  1.4 2.3  
Age at first sexual intercourse 
 
 0.3   0.0003 
9-14 years 18.0 13.5  15.5 90.6  
>= 15 years  82.0 86.5  84.5 9.2  
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No. of lifetime sex partners  
 
 0.004   0.00001 
3 21.7 39.4  21.6 42.0  
4 78.3 60.6  78.4 58.0  
No. of sex partners 5+ years 
older  
 
 0.3   0.003 
None 62.0 71.9  60.2 75.6  
1 38.0 28.1  39.8 24.4  
aHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
bNortheast, West, and Midwest combined 
 
Table 6. Odds of HPV infections among sexually active 14  26 year-old females by 
socio-demographic and sexual behavioral characteristics  
Characteristics HRa onocogenic types HPV  Any oncogenicb types HPV 
South  Otherc  South Otherc  
aORd aOR aOR aOR 
Race/Ethnicity 
 
   
Non-Hispanic White Ref. Ref. Ref. Ref. 
Non-Hispanic Black 1.79 (0.62-
5.2) 
0.85 (0.35-
2.1) 
1.73 (0.74-
4.0) 
1.09 (0.47-
2.6) 
Other  1.21 (0.56-
2.6) 
0.73 (0.39-
1.4) 
1.32 (0.60-
2.94) 
0.69 (0.40-
1.19) 
Marital Status 
 
   
Married Ref. Ref. Ref. Ref. 
Never married  1.56 (0.44-
5.5) 
12.79(4.8-
34.1)*** 
1.33 (0.18-
1.4) 
14.1 (6.3-
31.4)*** 
Divorced/separated/co
habitating 
1.62 (0.47-
5.5) 
6.09 
(2.2=16.6)**
* 
1.41 (0.36-
5.5) 
6.13 (2.4-
15.8)*** 
Federal poverty level 
 
   
<100% Ref. Ref. Ref. Ref. 
100-299% 0.59 (0.25-
1.4) 
1.79 (0.51-
6.2) 
0.50 (0.17-
1.4) 
2.18 (0.59-
8.0) 
300-499% 0.36 (0.17-
0.75)** 
1.59 (0.65-
3.9) 
0.41 (0.17-
0.99)* 
1.32 (0.57-
3.1) 
 500%  0.52 (0.13-
2.2) 
1.01 (0.31-
3.2) 
0.36 (0.07-
1.9) 
1.16 (0.41-
3.3) 
Health insurance 
 
   
No Ref. Ref. Ref. Ref. 
Yes 2.17 (0.79-
5.9) 
0.66 (0.27-
1.6) 
2.48 (1.23-
5.02)** 
0.60 (0.24-
1.51) 
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No. of sex partners 5+ 
years older  
 
   
None Ref. Ref. Ref. Ref. 
1 0.65 (0.24-
1.8) 
1.32 (0.66-
2.7) 
0.94 (0.44-
1.97) 
1.43 (0.68-
3.0) 
No. of lifetime sex 
partners  
 
   
3 Ref. Ref. Ref. Ref. 
4 8.27 (2.8-
24.4)*** 
4.03 (2.2-
7.4)*** 
8.51 (3.7-
19.6)*** 
4.40 (2.4-
8.2)*** 
aHPV  types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
bHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
 cNortheast, West, and Midwest combined 
dadjusted odds ratio 
*p<0.05; ** p<0.01; *** p<0.001  
 
Table 7. Odds of HPV infections among sexually active 27-59 year-old females by 
socio-demographic and sexual behavioral characteristics  
Characteristics HRa oncogenic types HPV Any oncogenicb types HPV 
South Otherc  South Otherc   
aORd aORd aORd aORd 
Race/Ethnicity 
 
   
Non-Hispanic White Ref. Ref. Ref. Ref. 
Non-Hispanic Black 0.72 (0.32-
1.7) 
0.63 (0.25-
1.6) 
0.88 (0.36-
2.1) 
0.52 (0.22-
1.2) 
Other  0.57 (0.24-
1.3) 
0.76 (0.31-
1.8) 
0.71 (0.39-
1.29) 
0.78 (0.36-
1.7) 
Marital Status 
 
   
Married Ref. Ref. Ref. Ref. 
Never married  5.14 (1.7-
15.2)** 
2.38 (1.23-
4.6)** 
4.27 (1.44-
12.6)** 
2.20 (1.34-
3.61)** 
Divorced/separated/coh
abitating 
2.98 (0.98-
9.1) 
4.26 (1.37-
13.3)* 
2.09 (0.69-
7.5) 
4.16 (1.76-
9.8)** 
Federal poverty level 
 
   
<100% Ref. Ref. Ref. Ref. 
100-299% 0.57 (0.15-
2.2) 
0.51 (0.19-
1.4) 
0.56 (0.15-
2.2) 
0.58 (0.26-
1.3) 
300-499% 1.12 (0.52-
2.4) 
0.26 (0.10-
0.66)** 
1.32 (0.50-
3.5) 
0.34 (0.15-
0.78)* 
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 500%  0.79 (0.33-
1.9) 
0.57 (0.25-
1.28) 
0.80 (0.38-
1.7) 
0.69 (0.31-
1.5) 
Health insurance 
 
   
No Ref. Ref. Ref. Ref. 
Yes 0.58 (0.27-
1.2) 
0.92 (0.30-
2.78) 
0.45 (0.20-
1.02) 
0.97 (0.32-
2.9) 
No. of sex partners 5+ 
years older  
 
   
None Ref. Ref. Ref. Ref. 
1 1.92 (0.45-
8.3) 
1.84 (1.13-
3.0)** 
1.64 (0.40-
7.1) 
1.57 (0.92-
2.6) 
No. of lifetime sex 
partners  
 
   
3 Ref. Ref. Ref. Ref. 
4 1.32 (0.98-
2.23) 
3.78 (1.6-
9.0)** 
1.43 (0.8-
2.53)  
3.9 (1.9-
8.0)*** 
Age at first sexual 
intercourse 
 
   
9-14 years Ref. Ref. Ref. Ref. 
 15 years  1.26 (0.5-
3.2) 
0.87 (0.59-
1.3) 
.07 (0.42-
2.74) 
0.47 (0.24-
0.93)* 
 
aHPV  types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59  
bHPV types: 6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 55, 56, 58, and 59 
 cNortheast, West, and Midwest combined 
dadjusted odds ratio 
*p<0.05; ** p<0.01; *** p<0.001   
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Manuscript 2 
Impact of Virginia’s HPV Vaccine School-Entry Mandate on HPV 
Vaccination among 13  17 Year-Old Females  
Abstract 
The link between human papillomavirus (HPV) and anogenital cancers is well 
established in the literature. Many states have passed laws requiring funding for HPV 
education or vaccination.  Mandatory HPV vaccination policies have been considered and 
passed in several states; yet their effectiveness has not been evaluated. This study sought 
to assess the impact of Virginia’s HPV vaccine mandate for girls entering sixth grade on 
HPV vaccine uptake among adolescent females aged 13  17 years.   
 Data from the National Immunization Survey-Teen for the 2008  2012 period 
were used, and 3,203 adolescent females were included in the analysis. A difference-in-
differences estimation, and logistic regression with a policy-period interaction term were 
performed. Virginia was considered the treatment state, and South Carolina and 
Tennessee were the comparison states to account for non-policy factors that may have 
affected vaccination rates during the time period considered in the analysis.   
There was no evidence of an effect of the HPV vaccination policy on vaccination 
rates or on physician vaccination recommendation using either the difference-in-
differences analysis or the policy-period interaction term in the logistic regression. 
Physician recommendation was the factor most strongly associated with vaccination in 
the Virginia-South Carolina analysis (aOR=10.3; 95%CI: 6.4-16.6) and in the Virginia-
Tennessee analysis (aOR=9.33; 95%CI: 6.11  14.3).     
Study findings suggest that Virginia’s HPV vaccine mandate did not lead to a 
significant increase in HPV vaccination among adolescent females or physician 
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recommendations.  However, physician recommendation was strongly associated with 
vaccination.  
Background 
The link between human papillomavirus (HPV) and oropharyngeal, penile, anal, 
vulvar, vaginal, and cervical cancers is well established (Forman et al., 2012). To date, 
two HPV preventative vaccines have been licensed by the Food and Drug Administration 
(Centers for Disease Control and Prevention, 2010a, 2010b; U.S. Food and Drug 
Administration, 2014).  The Advisory Committee on Immunization Practices (ACIP) 
recommends routine HPV immunization for 11  12 year-old adolescents (Centers for 
Disease Control and Prevention, 2012). HPV vaccination rates have increased in the 
United States, but they remain below Healthy People 2020’s goal of 80% (United States 
Department of Health and Human Services, 2014). In 2014, among adolescent females 
aged 13  17 years, the overall HPV vaccine initiation rates were higher among non-
Hispanic Blacks (66.4%) and Hispanics (66.3%) as compared to non-Hispanic Whites 
(56.1%) (Reagan-Steiner et al., 2015). However, HPV vaccine completion rates were 
very low for all ethnic groups, with Hispanics having the highest rates (46.9%) followed 
by Blacks (39.0%), Whites (37.5%), and Asians (35.7%) (Reagan-Steiner et al., 2015).  
In January 2007, three bills (SB1230, HB2035, SB1914) were introduced in 
Virginia to include HPV vaccine among vaccines required for school (Virginia 
Legislative Information System, 2007). As originally introduced, SB1230 and HB2035 
would require that females received three doses of the HPV vaccine (Virginia Legislative 
Information System, 2007). These bills did not include an opt-out option in addition to 
the regular exemptions for all other childhood vaccines (Virginia Legislative Information 
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System, 2007). The third bill, SB1914, would require females to receive three doses of 
the HPV vaccine, but it provided an opt-out option to parents after having read approved 
HPV educational materials (Virginia Legislative Information System, 2007).    
Before they were enacted, HB2035 and SB1230 incorporated SB 1914 based on 
the governor’s recommendation to include an opt-out option to parents since HPV is not 
transmissible in a school setting (Virginia Legislative Information System, 2007). 
HB2035 and SB1230 are identical and were both effective on October 1, 2008 (Virginia 
Legislative Information System, 2007). In the District of Columbia, a bill requiring HPV 
vaccination certificate was introduced in January 2007 (Council of the District of 
Columbia, 2007). Before the bill was passed, similar to the change in Virginia’s bills, it 
included an opt-out option for parents after having read the educational materials 
provided (Council of the District of Columbia, 2007).   
 More than twenty states have passed laws requiring funding for HPV education, 
or HPV vaccination while three others distribute free HPV vaccines through their health 
departments. Only the District of Columbia, Virginia, and Rhode Island have passed a 
HPV vaccine mandate (National Conference of States Legislatures, 2015). Mandatory 
school-entry HPV vaccine policy has been considered in several states; yet its impact on 
HPV vaccination has not been evaluated. This study assessed the impact of Virginia’s 
HPV vaccine mandate for school-entry for girls entering sixth grade on vaccination 
among 13  17 year-old adolescent females, using data from the National Immunization 
Survey-Teen (NIS-Teen).   
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Methods 
NIS-Teen Survey 
The purpose of the National Immunization Survey (NIS) is to estimate 
vaccination coverage among children 19 to 35 months old (Curtin, Lester et al., 2013). 
The NIS-Teen is a NIS appended survey, which uses random digit dialing telephone 
survey of households to provide an estimation of vaccination coverage among 
adolescents. NIS-Teen data collection is conducted in two stages: a household telephone 
survey that collects information on immunization status of adolescents from the teen’s 
parent or guardian, along with a permission request to contact the adolescent’s healthcare 
provider; and an immunization questionnaire mailed to teen’s healthcare providers 
(Curtin, Lester et al., 2013). For the telephone interview, the adult who is most informed 
about the child’s vaccinations is chosen to answer the questions. NIS-Teens’ detailed 
survey methodologies have been published elsewhere (Curtin, Lester et al., 2013). 
Study Design 
The current study used a pre-post design (difference-in-differences) with a 
comparison group from a natural experiment. A natural experiment is one in which an 
intervention varies through the natural occurrence of an event that is exogenous to the 
outcome of interest (Petticrew et al., 2005; Remler & Van Ryzin, 2011). It allows 
comparisons between a group that experiences the predetermined event and a group that 
did not (Petticrew et al., 2005; Remler & Van Ryzin, 2011). Although several methods 
have been used to assess effectiveness of public health policies, difference-in-differences 
is among the most widely used methods (Mason et al., 2015; Rajaram et al., 2014). 
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Difference-in-differences estimates the treatment effect on the treated group by 
subtracting the change in the outcome for the comparison group before and after the 
treatment from the change in the outcome for the treatment group before and after the 
treatment (Descy & Tessaring, 2004; Meyer, 1995a). Taking the difference of the group 
differences allows the control of unobserved differences that may bias the treatment 
effect estimate (Descy & Tessaring, 2004; Meyer, 1995a).  
Treatment and Comparison States 
Virginia is located in the Southern Black Belt, a part of the American South.  Its 
neighboring states in the Black Belt include North Carolina, Tennessee, and South 
Carolina.  North Carolina has enacted legislation requiring the Department of Health to 
provide HPV-related information to parents with children in grades five through 12 in 
2007 (National Conference of States Legislatures, 2015). As a result, North Carolina 
could not be a comparison state for Virginia. 
In South Carolina, a bill that would require HPV vaccine for girls after their 11th 
birthday or before entering the sixth grade was introduced in 2007. The bill was not 
enacted (National Conference of States Legislatures, 2015). Another bill that would 
require the Department of Health to offer HPV vaccine to girls before entering the 
seventh grade was introduced but was vetoed by the governor in June 2012. The House 
sustained the veto (National Conference of States Legislatures, 2015). HPV vaccine 
opponents expressed their concerns regarding side effects as well as potential increase in 
sexual promiscuity. On her side, Governor Haley stated lack of funding as her reason for 
vetoing the bill (South Carolina Radio Network, 2014). In Tennessee, mandatory HPV 
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vaccine policy was not introduced. A bill that would require the Department of Health to 
provide a report of the prevalence of HPV infection by age group accompanied by a HPV 
vaccine recommendation was introduced but not enacted (National Conference of States 
Legislatures, 2015).   
In the Black Belt, Virginia has the lowest poverty rate (10.4%) (U.S. Census 
Bureau, 2014b), and highest high school graduation rate among 18  24 year-olds (87%) 
for the 2007  2012 period compared to the other states in that region (U.S. Census 
Bureau, 2014a). Virginia is the only state in the region with median household income 
greater than the U.S. average. For the 2007  2010 period, Virginia’s median household 
income was $60,503 (U.S. Census Bureau, 2013a). For the same time period, the median 
household income was $42,295 in South Carolina, and $40,025 in Tennessee (U.S. 
Census Bureau, 2013a). During the 2007  2012 period, South Carolina had 82.3% of 
individuals aged 18  24 years with a high school diploma, and the poverty rate was 15.7% 
(U.S. Census Bureau, 2014a). During the same period, the poverty rate was 16.3%, and 
82.3% of individuals aged 18  24 years had a high school diploma in Tennessee (U.S. 
Census Bureau, 2014a). Both South Carolina and Tennessee were chosen as comparison 
states for Virginia for a more robust analysis. 
Sample and Population 
Virginia’s policy was implemented during the 2009  2010 school year (Virginia 
Department of Health, 2014). The pre-policy period was 2008 (before), the 
implementation year was 2009 (Virginia Department of Health, 2014), and the post-
policy period was 2010  2012 (after). The sample for this analysis included 1,064 female 
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adolescents aged 13  17 years living in Virginia, 1,084 living in South Carolina, and 
1,055 from Tennessee whose parent or guardian provided a response to HPV vaccination 
questions during the telephone survey. 
Variables  
Selected adolescent females’ race/ethnicity, age, state of residence, health 
insurance status, healthcare visits in the past 12 months, HPV vaccination history, 
maternal education level, maternal income, and maternal marital status were included in 
the analysis. For the purpose of this study, teens who had received at least one dose of the 
HPV vaccine series were classified as vaccinated. Immunization data from healthcare 
providers tend to be more accurate than self-reported. However, adolescents with 
sufficient immunization information from their healthcare provider are a subset of those 
who participated in the telephone interview. The kappa agreement between HPV 
vaccination status from the telephone survey and HPV vaccination status from provider 
was 92.5%.   
Statistical Analysis  
Weighted Pearson’s chi-square test to investigate the variation of different 
demographic factors between Virginia and its comparison states was performed. 
Additionally, we estimated a difference-in-differences model to quantify the difference in 
the change in vaccination rates between Virginia and South Carolina, and between 
Virginia and Tennessee before and after the policy implementation. Subsequently, a 
logistic regression analysis with ‘policy’ and ‘period’ interaction was performed to 
estimate the difference-in-differences in HPV vaccination among females living in 
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Virginia or its comparison states in order to control for demographic variables using the 
following model:  
Logit (Pr(Y =1|period, treatment, period*treatment, age…… physician recommendation)) 
=  + 1*state + 2 *period+ 3 *(period * state) + X (1)  
Y is HPV vaccination (1 = yes/0 = no), and X is a vector of control variables that 
included age, medical visits, maternal education, maternal income, and physician 
recommendation. Two logistic regression models were built to estimate difference-in-
differences in HPV vaccination.  The first model included the policy, the period, and the 
policy and period interaction variables.  For the second model, the demographic variables 
were added to the first model. To estimate difference-in-differences in physician 
recommendation while controlling for demographic variables, two logistic regression 
models were built using the following model:  
Logit (Pr(Y =1|period, treatment, period*treatment, age……and maternal income)) =  + 
1*state + 2 *period+ 3 *(period * state) + X (2)  
Y is HPV vaccine recommendation from a physician (1 = yes/0 = no), and X is a 
vector of control variables. A linktest was performed to assess the fit of the model. A p-
value <0.05 was used as the threshold for statistical significance. All statistical analyses 
were performed using STATA 13 (StataCorp, 2013), and all estimates were weighted to 
females aged 13-17 in the relevant states and years included in each analysis. 
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Results 
HPV Vaccination 
Vaccination rates followed similar trends in Virginia and South Carolina from 
2008 to 2012 (Figure 1). In the pre-policy year, vaccination rates were 33.9% in Virginia, 
20.8% in South Carolina, and 27.0% in Tennessee. In 2009, which is the year of the 
implementation of Virginia’s policy, vaccination rates were 37.9% in Virginia, 31.3% in 
South Carolina, and 40.7% in Tennessee. For the first year post-policy, vaccination rates 
were 47.1%, 39.7%, and 29.7% in Virginia, South Carolina, and Tennessee, respectively.  
In 2011, the rates were 42.0% for Virginia, 34.7% in South Carolina, and 36.1% in 
Tennessee. The rates were 48.8%, 36.1%, and 51.5% in Virginia, South Carolina, and 
Tennessee, respectively, in 2012 (Figure 1). The difference-in-differences in the 
vaccinated proportions between Virginia and South Carolina or Virginia and Tennessee 
was not significant (Table 1). 
[Figure 1 Here] 
[Table 1 Here] 
For the difference in selected socio-demographic and health utilization 
characteristics, in the pre-policy period, the sample of adolescent females in Virginia and 
South Carolina differed by vaccination status, race/ethnicity, health insurance coverage 
history, and household income (Table 2). For Virginia and Tennessee, adolescents 
differed by race and ethnicity, age, health insurance coverage history, and household 
income (Table 2). In the post-policy period, the sample of adolescent females in Virginia 
and South Carolina differed by vaccination status, race/ethnicity, number of medical 
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visits in the previous year, the proportion who had received a HPV vaccine 
recommendation, age at last medical visit, the proportion who had their 11–12-year-old 
medical check-up, maternal marital status, education, and income (Table 3). For Virginia 
and Tennessee, adolescents differed by vaccination status, race/ethnicity, mother’s 
marital status, mother’s education level, and income level (Table 3). 
[Table 2 Here] 
[Table 3 Here] 
In the first Virginia-South Carolina logistic regression model, adolescent females 
in Virginia had greater odds of being vaccinated compared to those living in South 
Carolina (aOR=1.95; 95%CI: 1.23 ̶ 3.07). Females in both states had greater odds of 
vaccination in the post- compared to the pre-policy period (aOR=2.22; 95%CI: 1.51 ̶ 
3.27). The policy and period interaction term was not significant (Table 4). In the second 
Virginia-South Carolina model, adolescent females who were recommended the vaccine 
had higher odds of being vaccinated (aOR=10.3; 95%CI: 6.4 ̶ 16.6). Also, those who had 
four to six medical visits the previous year had higher odds of vaccination compared to 
those who had fewer visits (aOR= 2.04; 95%CI: 1.24 ̶ 3.35) (Table 4). 
 In the first Virginia-Tennessee model, females were more likely to be vaccinated 
in the post- compared to the pre-policy period (aOR= 1.71; 95%CI: 1.19-2.44).  The 
policy variable and the interaction term were not significant (Table 4).  In the second 
Virginia-Tennessee model, females had higher odds of being vaccinated in the post- 
compared to the pre-policy period (aOR= 2.26; 95%CI: 1.02-5.00).  Females who were 
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recommended the vaccine had higher odds of being vaccinated (aOR=9.33; 95%CI: 6.11 ̶ 
14.3) (Table 4).   
[Table 4 Here] 
Physician Recommendation 
Physician recommendation rates followed similar trends in Virginia and South 
Carolina from 2008 to 2012 (Figure 2). In 2008, the pre-policy year, vaccine 
recommendation rates were 46.7% in Virginia, 41.2% in South Carolina, and 40.9% in 
Tennessee. In 2009, the year of the implementation of Virginia’s policy, vaccine 
recommendation rates were 52.6% in Virginia, 41.6% in South Carolina, and 48.5% in 
Tennessee. For the first post-policy year, vaccine recommendation rates were 51.2%, 
44.7%, and 49.5% in Virginia, South Carolina, and Tennessee, respectively. In 2011, the 
rates were 55.6% in Virginia, 48.0% in South Carolina, and 49.1% in Tennessee. The 
rates were 65.4%, 50.8%, and 66.5% in Virginia, South Carolina, and Tennessee, 
respectively, in 2012 (Figure 2).    
[Figure 2 Here] 
The difference-in-differences in the percentage of female adolescents who 
received physician recommendation for HPV vaccine between Virginia and South 
Carolina and between Virginia and Tennessee was not significant (Table 5). For the first 
Virginia-South Carolina logistic regression model predicting the odds for physician 
recommendation, none of the variables was significant. For the second model, females 
who had seven to nine medical visits had higher odds to receive a physician 
recommendation for HPV vaccine compared to those who had fewer visits (aOR= 2.36; 
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95%CI: 1.09 ̶ 5.11). Those whose family income was unknown had lower odds of 
receiving a HPV vaccine recommendation (aOR=0.33; 95%CI: 0.14 ̶ 0.76). Female 
adolescents who were continually insured since age 11 had lower odds of receiving a 
HPV vaccine recommendation (aOR=0.33; 95%CI: 0.17 ̶ 0.66) (Table 6).   
In the first Virginia-Tennessee model, the odds of HPV vaccine recommendation 
were higher in the post- compared to the pre-policy period (aOR=1.77; 95%CI: 1.28 ̶ 
2.45).  The remaining variables were not significant (Table 6). In the second model, 
females whose mother graduated high school (aOR=2.24; 95%CI: 1.09 ̶ 4.6), had some 
college education (aOR=3.14; 95%CI: 1.49 ̶ 6.59), or graduated college (aOR=2.87; 
95%CI: 1.34 ̶ 6.1) had higher odds of receiving a physician recommendation for the 
vaccine compared to those whose mother did not graduate from high school.  
Additionally, females living in household with income level above poverty and $75,000 
had lower odds of receiving a HPV vaccine recommendation compared to those in 
households of more than $75,000 (Table 6).   
[Table 5 Here] 
[Table 6 Here] 
Discussion 
There was no evidence of improvement in vaccination rates associated with the 
mandatory school-entry vaccination policy in either the Virginia-Tennessee or the 
Virginia-South Carolina comparisons. Results were similar in both the difference-in-
differences analysis and the logistic regression. Moreover, after we controlled for 
demographic factors, females in Virginia did not have higher odds of being vaccinated 
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compared to those either in South Carolina or Tennessee. Those who had more than three 
medical visits in the previous year had higher odds of being vaccinated. Females from all 
three states had higher odds of vaccination in the post- compared to the pre-policy period. 
HPV vaccine recommendation was consistently associated with HPV vaccination. This 
association is in agreement with the literature (Mazza, Petrovic, & Chakraborty, 2012; 
Perkins et al., 2013; Reiter, McRee, et al., 2013; Vadaparampil et al., 2011). However, 
there was also no evidence that the mandatory vaccination for school-entry increased 
physician recommendations for the vaccine.   
There are several reasons why Virginia’s HPV vaccine school-entry mandate may 
not have resulted in a significant increase in HPV vaccination. First, parents or guardians 
of females entering sixth grade were not required to provide proof of HPV immunization 
like they do for other required vaccines (Virginia Department of Health, 2014). Second, 
after reading the HPV educational materials, parents who opposed HPV vaccination for 
their daughters could opt-out without having to provide any documentation for their 
refusal. Additionally, parents in Virginia have not only expressed concerns regarding the 
safety of the vaccine (Liddon, Hood, & Leichliter, 2012), but also about the possibility 
that adolescents will interpret their receipt of the vaccine as a license to be sexually active 
or to practice risky sexual  behaviors (Scarinci, Garcés-Palacio, & Partridge, 2007; 
Schuler, Reiter, Smith, Brewer, & Hill, 2011). Moreover, negative opinions regarding the 
HPV vaccine mandate were common in the media (Casciotti et al., 2014), and several 
parental rights groups viewed the mandate as an infringement on parental rights despite 
the loose opt-out option (Casciotti et al., 2014; Natural News Network, 2015; PR 
Newswire, 2015). Reasons cited for mandate opposition included government distrust, 
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sexual transmission concern, and infringement of parental autonomy (Casciotti et al., 
2014). Furthermore, since the passing of the mandate, the legislature has introduced 
several bills to repeal it (National Conference of States Legislatures, 2015). Evidently, 
Virginia’s socio-political environment did not facilitate the effectiveness of the mandate.   
Strengths and Limitations 
Although this study is among the firsts to assess the impact of Virginia’s mandate 
on HPV vaccination, it is not without limitations. One major limitation of the research is 
the use of pooled cross-sectional data. Moreover, the policy and the control states have 
some similarities but are not exactly identical. Difference-in-differences assumes that 
time-varying unmeasured characteristics are constant over the time period in the policy 
state and do not correlate with HPV vaccinations. Although we verified that any 
significant change did not take place for some of the unmeasured characteristics in the 
dataset such as bills directly impacting Medicaid expansion under the Affordable Care 
Act and Medicaid and CHIP eligibility. This assumption could not be fully tested.   
Despite the aforementioned limitations, the present study used data from a 
nationally representative sample that is robust against selection bias. Additionally, this 
study is among the first few to assess the impact of Virginia’s HPV vaccine mandate for 
school-entry on vaccine uptake among female adolescents while similar policies are 
being considered in several states. Moreover, the initial sample size decreased for the 
logistic regression models due to missing observations, but the power did not fall below 
80%. Furthermore, a general pitfall in policy analysis is “policy endogeneity,” which 
would occur, in this case, if Virginia’s HPV vaccine school-entry mandate were adopted 
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to increase HPV vaccination, because of low HPV vaccination in Virginia. There was no 
indication that Virginia adopted the policy mandate due to low HPV vaccination.  Prior to 
the passing of the mandate, Virginia’s HPV vaccination rates were higher than those of 
the neighboring states. Therefore, there is no evidence of “policy endogeneity”.  
Implications for Practice 
The current study assessed an important policy that may have served as a model 
for other states with high cervical cancer rates. Results revealed that the HPV vaccine 
mandate for school-entry did not yield the intended results. However, these results do not 
suggest that HPV vaccine mandates cannot be successful. The socio-political 
environment in which the mandate was passed is an important factor that may influence 
its impact. In Virginia, the socio-political context was not favorable to the mandate. Most 
parents had a positive perception of physician recommendation even if they chose not to 
vaccinate their adolescents (Perkins et al., 2014). Therefore, it is necessary for policy-
makers to understand that physician recommendation must accompany the mandate in 
order for it to yield the desired results. Since the introduction of HPV vaccine, the 
prevalence of HPV infection has decreased by more than 50% among 14-19 year-old 
females in the United States (Markowitz et al., 2013), despite low HPV vaccination rates.  
We must continue to educate parents about the vaccine’s effectiveness at reducing HPV 
infection from the types covered by the vaccine and the implications of this decline in 
order to facilitate physician recommendation. 
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Conclusion 
Study findings did not indicate that Virginia’s HPV vaccine mandate led to a 
significant increase in HPV vaccination among adolescent females. Despite Virginia’s 
mandate, physician recommendation remains the consistent predictor of HPV 
vaccination. While the mandate may be viewed as infringement of parental rights by 
some, a physician recommendation is not viewed as such. As a result, efforts to 
encourage physician recommendation must continue along with research to better 
understand the facilitators of physician recommendation.    
References 
Casciotti, D. M., Smith, K. C., Andon, L., Vernick, J., Tsui, A., & Klassen, A. C. (2014). 
Print news coverage of school-based human papillomavirus vaccine mandates. 
Journal of School Health, 84(2), 71–81. doi:10.1111/josh.12126 
Centers for Disease Control and Prevention. (2010a). FDA licensure of bivalent human 
papillomirus vaccine (HPV2, Cervarix) for use in females and updated HPV 
vaccination recommendations from the Advisory Committee on Immunization 
Practices (ACIP). MMWR, 59(20), 625–629. 
Centers for Disease Control and Prevention. (2010b). FDA licensure of quadrivalent 
human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from 
the Advisory Committee on Immunization Practices (ACIP). MMWR, 56(20), 630–
632. 
Centers for Disease Control and Prevention. (2012). Advisory Committee on 
Immunization Practices: human papillomavirus vaccine resolution. Retrieved March 
13, 2015, from 
http://www.cdc.gov/vaccines/programs/vfc/providers/resolutions.html 
Council of the District of Columbia. (2007). Human Papillomavirus vaccination and 
reporting Act of 2007. Retrieved February 26, 2016, from 
http://lims.dccouncil.us/Legislation/B17-0030?FromSearchResults=true 
Curtin, Lester, R., Mohadjer, L. K., Dohrmann, S. M., Kruszan-Moran, D., Mirel, L. B., 
Carroll, M. D., … Johnson, C. L. (2013). National Health and Nutrition Examination 
Survey: Sample design, 2007 – 2010. Vital and Health Statistics, 2(160). 
52 
 
Descy, P., & Tessaring, M. (2004). Evaluation and impact of education and training: the 
value of learning. Retrieved from 
http://www.trainingvillage.gr/etv/projects_Networks/researchlab/ 
Forman, D., de Martel, C., Lacey, C. J., Soerjomataram, I., Lortet-Tieulent, J., Bruni, L., 
… Franceschi, S. (2012). Global burden of human papillomavirus and related 
diseases. Vaccine, 30(Suppl 5). doi:10.1016/j.vaccine.2012.07.055 
Liddon, N. C., Hood, J. E., & Leichliter, J. S. (2012). Intent to receive HPV vaccine and 
reasons for not vaccinating among unvaccinated adolescent and young women: 
findings from the 2006-2008 National Survey of Family Growth. Vaccine, 30(16), 
2676–82. doi:10.1016/j.vaccine.2012.02.007 
Markowitz, L. E., Hariri, S., Lin, C., Dunne, E. F., Steinau, M., McQuillan, G., & Unger, 
E. R. (2013). Reduction in human papillomavirus (HPV) prevalence among young 
women following HPV vaccine introduction in the United States, National Health 
and Nutrition Examination Surveys, 2003-2010. The Journal of Infectious Diseases, 
208(3), 385–93. doi:10.1093/infdis/jit192 
Mason, T., Sutton, M., Whittaker, W., McSweeney, T., Millar, T., Donmall, M., … 
Pierce, M. (2015). The impact of paying treatment providers for outcomes: 
Difference-in-differences analysis of the “payment by results for drugs recovery” 
pilot. Addiction, 110(7), 1120–8. doi:10.1111/add.12920 
Mazza, D., Petrovic, K., & Chakraborty, S. (2012). HPV vaccination of adult women: an 
audit of Australian general practitioners. The Australian & New Zealand Journal of 
Obstetrics & Gynaecology, 52(6), 528–33. doi:10.1111/ajo.12002 
Meyer, B. D. (1995). Natural and Quasi-Experiments in Economics. Journal of Business 
& Economic Statistics, 13(2), 151. doi:10.2307/1392369 
National Conference of States Legislatures. (2015). HPV Vaccine: State Legislation and 
Statutes. Retrieved December 24, 2015, from 
http://www.ncsl.org/research/health/hpv-vaccine-state-legislation-and-statutes.aspx 
Natural News Network. (2015). Virginia law guaranteeing parents’ medical rights routed 
by mandatory HPV vaccination - NaturalNews.com. Retrieved December 23, 2015, 
from http://www.naturalnews.com/021628_HPV_vaccine_Merck.html 
Perkins, R. B., Apte, G., Marquez, C., Porter, C., Belizaire, M., Clark, J. A., & Pierre-
joseph, N. (2013). Factors Affecting Human Papillomavirus Vaccine Use Among 
White , Black and Latino Parents of Sons. The Pediatric Infectious Disease Journal, 
32(1), 38–44. doi:10.1097/INF.0b013e31826f53e3 
 
 
53 
 
Perkins, R. B., Clark, J. a, Apte, G., Vercruysse, J. L., Sumner, J. J., Wall-Haas, C. L., … 
Pierre-Joseph, N. (2014). Missed opportunities for HPV vaccination in adolescent 
girls: a qualitative study. Pediatrics, 134(3), e666–74. doi:10.1542/peds.2014-0442 
Petticrew, M., Cummins, S., Ferrell, C., Findlay, A., Higgins, C., Hoy, C., … Sparks, L. 
(2005). Natural experiments: an underused tool for public health? Public Health, 
119(9), 751–7. doi:10.1016/j.puhe.2004.11.008 
PR Newswire. (2015). Virginia Committee Ignores Parental Rights, Health Concerns of 
HPV Vaccine Mandate. Retrieved December 23, 2015, from 
http://www.prnewswire.com/news-releases/virginia-committee-ignores-parental-
rights-health-concerns-of-hpv-vaccine-mandate-57101112.html?$G1Ref 
Rajaram, R., Chung, J. W., Jones, A. T., Cohen, M. E., Dahlke, A. R., Ko, C. Y., … 
Bilimoria, K. Y. (2014). Association of the 2011 ACGME resident duty hour reform 
with general surgery patient outcomes and with resident examination performance. 
JAMA, 312(22), 2374–2384. doi:10.1001/jama.2014.15277 
Reagan-Steiner, S., Yankey, D., Jeyarajah, J., Elam-Evans, L. D., Singleton, J. A., Curtis, 
C. R., … Stokley, S. (2015). National, Regional, State, and Selected Local Area 
Vaccination Coverage among Adolescents Aged 13-17--United States, 2014. 
MMWR, 64(29), 784–792. Retrieved from 
http://www.ncbi.nlm.nih.gov/pubmed/26225479 
Reiter, P. L., McRee, A.-L., Pepper, J. K., Gilkey, M. B., Galbraith, K. V, & Brewer, N. 
T. (2013). Longitudinal predictors of human papillomavirus vaccination among a 
national sample of adolescent males. American Journal of Public Health, 103(8), 
1419–27. doi:10.2105/AJPH.2012.301189 
Remler, D. K., & Van Ryzin, G. G. (2011). Natural and quasi experiments. In Research 
methods in practice: Strategies for description and causation (pp. 427–464). 
Thousand Oaks: California: Sage. 
Scarinci, I. C., Garcés-Palacio, I. C., & Partridge, E. E. (2007). An examination of 
acceptability of HPV vaccination among African American women and Latina 
immigrants. Journal of Women’s Health, 16(8), 1224–33. 
doi:10.1089/jwh.2006.0175 
Schuler, C. L., Reiter, P. L., Smith, J. S., Brewer, T., & Hill, C. (2011). HPV vaccine and 
behavioral disinhibition. Sexually Transmitted Infections, 87(4), 349–353. 
doi:10.1136/sti.2010.048017.HPV 
South Carolina Radio Network. (2014). CDC: South Carolina among most improved fro 
HPV vaccine availability. Retrieved March 11, 2016, from 
http://www.southcarolinaradionetwork.com/?s=HPV+vaccine 
54 
 
StataCorp. (2013). Stata Statistical Software: Release 13. College Station, Texas: 
StataCorp LP. 
U.S. Census Bureau. (2013). Income. Retrieved April 27, 2015, from 
http://www.census.gov/hhes/www/income/ 
U.S. Census Bureau. (2014a). Educational attainment. Retrieved from 
httos://www.census.gov/hhes/socdemo/education/ 
U.S. Census Bureau. (2014b). Poverty. Retrieved April 27, 2015, from 
http://www.census.gov/hhes/www/poverty/ 
U.S. Food and Drug Administration. (2014). Press Announcements - FDA approves 
Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 
Retrieved June 18, 2015, from 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm 
United States Department of Health and Human Services. (2014). Healthy People 2020 
topics and objectives:Immunization and infectious diseases. Retrieved March 5, 
2016, from https://www.healthypeople.gov/2020/topics-
objectives/topic/immunization-and-infectious-diseases 
Vadaparampil, S. T., Kahn, J. A., Salmon, D., Lee, J.-H., Quinn, G. P., Roetzheim, R., … 
Giuliano, A. R. (2011). Missed clinical opportunities: provider recommendations for 
HPV vaccination for 11-12 year old girls are limited. Vaccine, 29(47), 8634–41. 
doi:10.1016/j.vaccine.2011.09.006 
Virginia Department of Health. (2014). School and Day Care Minimum Immunization 
Requirements. Retrieved December 24, 2015, from 
http://www.vdh.virginia.gov/epidemiology/immunization/requirements.htm 
Virginia Legislative Information System. (2007). Bill Tracking - 2007 Session 
Legislation. Retrieved February 26, 2016, from http://leg1.state.va.us/cgi-
bin/legp504.exe?071+ful+CHAP0858 
 
 
 
 
 
55 
 
Figure 1. HPV vaccination trends in Virginia, South Carolina, and Tennessee, 2008-
2012 
 
*Policy implementation year 
1 1 dose of HPV vaccine 
 
Table 1. Difference-in-differences in HPV vaccination1 rates, Virginia and South 
Carolina, and Virginia and Tennessee 
 
N=2,119 Pre-policy Period 
 (2008) 
Post-policy period  
(2010-12) 
Difference 
Virginia 0.339 0.460 0.121 
South Carolina 0.208 0.368 0.160 
Difference-in-differences     -0.039 
N= 2,139    
Virginia 0.339 0.460 0.121 
Tennessee 0.27 0.387 0.117 
Difference-in-differences   0.004 
* p <0.05 
1 1 dose of HPV vaccine 
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Table 2. Difference in selected demographic characteristics in Virginia and South 
Carolina, and Virginia and Tennessee pre-policy period 
 
 Pre-policy period (2008) 
Characteristics Virginia 
(n=298) 
S. Carolina 
(n=295) 
p-
value 
Tennessee 
(n=239) 
p-
value 
 %(95% CI) %(95% CI) %(95% CI) 
Vaccinated   0.004  0.14 
No 66.2 (59.0-
72.6) 
79.2 (73.0-84.3)  73.0 (66.5-
78.6) 
 
Yes 33.8 (27-41) 20.8(15.8-27.0)  27.0 (21.3-
33.5) 
 
Race and ethnicity   0.04  0.042 
Hispanic 6.9 (4.2-11.3) 4.7 (2.4-8.5)  3.2 (1.5-6.9)  
White 64.7 (57.2-
71.6) 
55.4(48.7-61.8)  70.9 (63.6-
77.3) 
 
Black 24.4 (18.0-
32.2) 
36.8 (30.5-43.7)  22.3 (16.3-
29.8) 
 
Other 3.9 (2.2-6.7) 3.2(1.8-5.7)  3.6 (1.9-6.5)  
Teen's age   0.47  0.048 
13-15years 64.7 (57.6-
71.3) 
61.3(54.8-67.4)  55.0 (48.3-
61.6) 
 
16-17 years 35.3 (28.7-
42.4) 
38.7(32.6-45.2)  45.0 (38.4-
51.7) 
 
No. of medical 
visits last year 
  0.57  0.36 
1 to 3 72.8 (66.1-
78.6) 
77.1(70.8-82.4)  75.5(69.3-
80.8) 
 
4 to 6 22.7(17.3-
29.1) 
19.6 (14.7-25.7)  17.9(13.2-
23.9) 
 
7 to 9 4.6(2.4-8.5) 3.3 (1.5-6.9)  6.6(4.3-9.9)  
Ever been insured 
since age 11?  
  0.049  0.009 
yes 4.0 (1.8-8.5) 9.4(6.1-14.2)  12.2 (7.8-18.6)  
No 96.0 (91.5-
98.2) 
90.6(85.8-93.9)  87.8 (81.4-
92.2) 
 
HPV vaccine 
recommendation 
  0.27  0.24 
No 53.3(45.9-
60.5) 
58.8 (52.0-65.3)  59.1(52.3-
65.5) 
 
Yes 46.7 (39.5-
54.1) 
41.2(34.7-48.0)  40.9(34.5-
47.7) 
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Age at last medical 
visits 
  0.63   
less than 11 years 4.9(2.4-9.6) 6.0 (3.7-9.6)  4.7(2.7-8.2) 0.94 
11 years or older 95.1(90.4-
97.6) 
94.0 (90.4-96.4)  95.3(91.8-
97.3) 
 
Teen had an 11-12-
year-old check-up? 
  0.09   
No 7.6(4.0-13.7) 13.7 (9.5-19.3)  9.6(6.1-14.7) 0.53 
Yes 92.4 (86.3-
96.0) 
86.3 (80.7-90.5)  90.4 (85-3-
93.9) 
 
Marital status of 
mother 
  0.49  0.23 
Married 54.2 (38.0-
69.6) 
61.2 (49.2-72.1)  67.3(51.7-
79.8) 
 
Not married 45.8 (30.4-
43.6) 
88.8 (27.9-50.8)  32.7 (20.2-
48.3) 
 
Mother's education 
level 
  0.13  0.33 
Less than high 
school 
9.5(6.0-14.8) 11.5(8.1-16.2)  12.8(8.6-18.6)  
High school 27.4 (21.1-
34.8) 
31.6(25.4-38.5)  32.9 (26.6-
40.0) 
 
Some College 25.7 (20.0-
32.3) 
30.6(25.1-36.8)  24.0 (18.9-
29.8) 
 
college graduate 37.4 (31.0-
44.3) 
26.2(21.4-31.7)  30.3 (25.4-
36.2) 
 
Household income   0.005  0.001
4 
Above poverty 
>$75,000 
47.0 (40.0-
54.2) 
29.7(24.3-35.7)  29.4 (24.2-
35.2)  
 
Above poverty  
<= $75,000 
42.6 (35.5-
49.9) 
48.5(42.0-
54.98) 
 51.2 (44.6-
57.8) 
 
Below poverty 
level 
7.2(4.3-11.8) 16.6(12.1-22.2)  14.0 (9.5-20.2)  
Unknown 3.2 (1.5-6.6) 5.2(3.2-8.5)  5.4 (3.2-8.9)  
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Table 3. Difference in selected demographic characteristics in Virginia and South 
Carolina, and Virginia and Tennessee post-policy period 
 Post-policy period (2010-12) 
Characteristics Virginia 
(n=766) 
S. Carolina  
(n=789) 
p-
value 
Tennessee 
(n=816) 
p-
value 
 %(95% CI)  %(95% CI)  %(95% CI) 
Vaccinated   0.004  0.023 
No 54.0 (49.6-
58.5) 
63.2 (58.7-67.4)  61.3 (56.9-
65.5) 
 
Yes 46.0 (41.5-
50.4) 
36.8 (32.6-41.3)  38.7 (34.5-
43.1) 
 
Race and ethnicity   7E-
04 
 0.003 
Hispanic 8.6 (6.2-
11.8) 
4.4(3.0-6.4)  4.5 (3.0-6.5)  
White 59.7 (55.2-
64.0) 
56.6 (52.0-61.0)  70.2 (65.9-
74.3) 
 
Black 24.1 (20.1-
28.7) 
34.0 (29.6-38.7)  20.3 (16.6-
24.6) 
 
Other 7.6 (5.9-9.6) 5.0 (3.3-7.6)  5.0 (3.4-7.2)  
Teen's age   0.41  0.7 
13-15years 61.4 (57.2-
65.4) 
63.8 (59.0-67.9)  60.2 (60.0-
64.3) 
 
16-17 years 38.6 (34.6-
42.8) 
36.2(32.1-40.5)  39.8 (35.7-
44.0) 
 
No. of medical 
visits last year 
  0.026  0.16 
1 to 3 79.8 (76.2-
82.9) 
73.2 (69.0-77.0)  78.0 (74.3-
81.3) 
 
4 to 6 16.6 (13.7-
19.9) 
20.5 (17.0-24.4)  15.8 (13.0-
19.2) 
 
7 to 9 3.7 (2.4-5.6) 6.3 (4.5-8.8)  6.1 (4.4-8.4)  
Ever been insured 
since age 11?  
  0.09  0.74 
yes 7.1 (4.5-
11.0) 
11.6 (8.2-16.2)  7.9 (5.2-11.6)  
No 92.9 (89.0-
95.5) 
88.4 (83.8-91.8)  92.1 (89.4-
94.8) 
 
HPV vaccine 
recommendation 
  0.003  0.46 
No 42.6 (38.3-
47.0) 
52.2 (47.7-56.6)  44.9 (40.6-
49.3) 
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Yes 57.4 
(53.61.7) 
47.8 (43.4-52.3)  55.1 (50.7-
59.4) 
 
Age at last medical 
visits 
  0.004  0.14 
less than 11 years 2.4 (1.5-3.8) 5.8(3.8-8.6)  3.9 (2.5-6.1)  
11 years or older 97.6 (96.2-
98.5) 
94.2 (91.4 -
96.2) 
 96.1 (93.9-
97.5) 
 
Teen had an 11-12 
year-old check up? 
  0.032  0.34 
No 6.7 (4.7-9.4) 10.8 (8.2-14.3)  91.7 (89.1-
93.7) 
 
Yes 93.3 (90.6-
95.3) 
89.2 (85.7-91.8)  8.3 (6.3-10.9)  
Marital status of 
mother 
  1E-
05 
 0.001 
Married 74.7 (70.4-
78.6) 
56.9 (52.3-61.4)  64.8 (60.4-
69.0) 
 
Not married 25.3 (21.4-
29.7) 
43.1 (38.6-47.7)  35.2 (31.0 -
39.6) 
 
Mother's education 
level 
  1E-
05 
 0.002 
Less than high 
school 
7.6 (5.5-
10.3) 
11.1(8.4-14.6)  9.9 (7.6-12.9)  
High school 23.4 (19.6-
27.7) 
30.0 (25.9-34.5)  29.9 (26.0-
34.0) 
 
Some College 23.6 (20.1-
27.5) 
29.8(25.9-33.9)  26.8 (23.1-
30.8) 
 
college graduate 45.4 (41.3-
49.7) 
29.1 (25.7-32.7)  33.4 (29.7-
37.5) 
 
Household income   1E-
05 
 1E-
05 
Above poverty 
>$75,000 
44.0 (39.9-
48.1) 
25.0 (22.0-28.3)  27.1 (23.8-
30.6) 
 
Above poverty  
<= $75,000 
35.9 (31.8-
40.1) 
39.7 (35.5-44.0)  43.5 (39.3-
47.8) 
 
Below poverty 
level 
13.6 (10.4-
17.6) 
30.0 (25.7-34.7)  23.7 (19.9-
28.0) 
 
Unknown 6.6 (4.7-9.1) 5.3 (3.8-7.3)  5.8 (4.1-8.0)  
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Table 4. Odds ratios for HPV vaccination according to selected characteristics, 
Virginia, South Carolina, and Tennessee 
 Virginia & S. Carolina Virginia and Tennessee 
Characteristic
s 
Model 2 
(n=2,119) 
Model 2 
 (n= 957) 
Model 1 
(n=2,119) 
Model 2  
(n=976) 
aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) 
Policy 
implemented 
    
No Ref. Ref. Ref. Ref. 
Yes 1.95 (1.23-
3.07)** 
3.37 (0.81-
14.0) 
1.38 (0.90-
2.13) 
3.32 (0.94-11.7) 
Period     
Pre Ref. Ref. Ref. Ref. 
Post 2.22(1.51-
3.27)*** 
2.72 (0.99 -
7.47) 
1.71 (1.19-
2.44**) 
2.26 (1.02-5.0)* 
Interaction 
term 
    
Policy*perio
d 
0.75 (0.44-
1.26) 
0.52 (0.12-
2.23) 
0.97 (0.60-
1.61) 
0.56 (0.15-2.12) 
vaccine 
recommendat
ion 
    
No  Ref.  Ref. 
Yes  10.3 (6.4-
16.6)*** 
 9.33 (6.11-
14.27)*** 
Race/ 
ethnicity 
    
White  Ref.  Ref. 
Hispanic  0.77 (0.36-
1.61) 
 0.77 (0.35-1.69) 
Black  1.34 (0.78-
2.34) 
 0.74 (0.42-1.29) 
Other  1.57 (0.71-
3.49) 
 0.97 (0.43-2.20) 
Maternal  
education  
    
Less than 
high school 
 Ref.  Ref. 
High school  1.21 (0.48-
3.07) 
 1.84 (0.83-4.9) 
Some 
College 
 0.76 (0.29-
1.97) 
 1.13 (0.51-2.52) 
college 
graduate 
 0.66(0.26-
1.71) 
 1.00 (0.46-2.20) 
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Household 
income  
    
Above 
poverty 
>$75,000 
 Ref.  Ref. 
Above 
poverty  
<= $75,000 
 0.93 (0.58-
1.49) 
 0.85 (0.53-1.36) 
Below 
poverty 
 1.13 (0.53-
2.44) 
 1.38 (0.67-2.87) 
Unknown  1.05 (0.37-
2.95) 
 0.93 (0.36-2.38) 
No. of 
medical visits  
last year 
    
1 to 3  Ref.  Ref. 
4 to 6  2.04 (1.24-
3.35)** 
 1.63 (1.03-2.58)* 
7 to 9  1.65 (0.73-
3.72) 
 2.52 (1.04-6.11)* 
Ever been 
uninsured 
since age 11 
    
yes  Ref.  Ref. 
No  0.65 (0.32-
1.31) 
 0.646 (0.31-1.36) 
Mother's 
marital status 
    
Married  Ref.  Ref.  
Not married  0.96 (0.54-
1.71) 
 1.57 (0.92-2.70) 
Teen's age     
13-15 years  Ref.  Ref.  
16-17 years  1.07 (0.71-
1.62) 
 1.21 (0.812-1.79) 
Had 11-12-
year-old 
check-up? 
    
Yes  Ref.  Ref. 
No  1.11 (0.60-
2.07) 
 0.71 (0.36-1.39) 
 
 
62 
 
Figure 2. Physician recommendation trends in Virginia, South Carolina, and 
Tennessee, 2008-2012 
 
*Policy implementation year  
 
 
Table 5. Difference-in-differences in HPV vaccine recommendation rates for 
Virginia and South Carolina, and Virginia and Tennessee  
N= 2163 Pre-policy Period 
 (2008) 
Post-policy period  
(2010-12) 
Difference 
Virginia 0.467 0.574 0.107 
South Carolina 0.412 0.478 0.066 
Difference-in-differences     0.041 
N= 2196    
Virginia 0.467 0.574 0.107 
Tennessee 0.409 0.551 0.142 
Difference-in-differences   0.035 
* p<0.05; ** p<0.01; *** p<0.001 
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Table 6. Odds ratios for physician recommendation according to selected 
characteristics, Virginia and South Carolina, and Virginia and Tennessee 
 Virginia and South 
Carolina 
Virginia and Tennessee 
Characteristic
s 
Model 1 
(N=2,163) 
Model 2 
(N= 1000) 
Model 1  
(N=2196) 
Model 2 
 (N= 1031) 
aOR (95%CI) aOR 
(95%CI) 
aOR (95%CI) aOR (95%CI) 
Policy 
implemented 
 
   
No Ref. Ref. Ref. Ref. 
Yes 1.25 (0.84-
1.87) 
1.43 (0.43-
4.71) 
1.27 (0.85-1.89) 0.94 (0.32-2.78) 
Period 
 
   
Pre Ref. Ref. Ref. Ref. 
Post 1.31 (0.94-
1.81) 
1.48 (0.70-
3.14) 
1.77(1.28-
2.45)** 
1.18 (0.58-2.37) 
Interaction 
term 
 
   
Policy*period 1.17 (0.73-
1.89) 
0.78 (0.23-
2.67) 
0.87 (0.54-1.39) 1.07 (0.34-3.38) 
Race and 
ethnicity 
 
   
Non-Hispanic 
White 
 Ref.  Ref. 
Hispanic  0.78 (0.33-
1.85) 
 1.28 (0.55-2.98) 
Non-Hispanic 
Black 
 0.74 (0.46-
1.21) 
 0.79 (0.48-1.29) 
Other  0.77 (0.39-
1.54) 
 0.55 (0.30-1.01) 
Mother's 
education level 
 
   
Less than high 
school 
 Ref.  Ref. 
High school  1.41 (0.69-
2.93) 
 2.24 (1.09-4.61)* 
Some College  1.45 (0.70-
3.0) 
 3.14 (1.49-
6.59)** 
College 
graduate 
 1.85 (0.90-
3.83) 
 2.87 (1.34-
6.10)** 
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Household 
income  
 
   
Above poverty 
>$75,000 
 Ref.  Ref. 
Above poverty 
<= $75,000 
 0.64 (0.41-
1.01) 
 0.49 (0.31-
0.76)** 
Below poverty 
level 
 0.55 (0.28-
1.08) 
 0.73 (0.38-1.38) 
Unknown  0.33 (0.14-
0.76)* 
 0.60 (0.25-1.45) 
No. of medical 
visits last year  
 
   
1 to 3  Ref.  Ref. 
4 to 6  1.04 (0.65-
1.65) 
 1.43 (0.91-2.24) 
7 to 9  2.36 (1.09-
5.11)* 
 1.79 (0.25-1.45) 
Ever been 
uninsured since 
age 11? 
 
   
yes  Ref.  Ref. 
No  0.33 (0.17-
0.66)** 
 0.76 (0.40-1.58) 
Mother's 
marital status 
 
   
Married  Ref.  Ref. 
Not married  0.82(0.50-
1.34) 
 1.14 (0.71-1.85) 
Teen's age 
 
   
13-15 years  Ref.  Ref. 
16-17 years  1.09(0.74-
1.61) 
 1.09 (0.76-1.56) 
Teen had an 
11-12 year-old 
check-up 
 
   
Yes  Ref.  Ref. 
No  0.62 (0.33-
1.17) 
 0.96 (0.50-1.83) 
* p<0.05; ** p<0.01; *** p<0.001 
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Manuscript 3 
Impact of Louisiana’s HPV Vaccine Awareness Policy on HPV Vaccination among 
13  17 Year-Old Females 
Abstract 
The Advisory Committee on Immunization Practices recommends routine human 
papillomavirus (HPV) immunization for 11 ̶ 12 year-old adolescents. In 2008, Louisiana 
required the school boards to distribute HPV vaccine information to parents or guardian 
of students in grades 6 ̶ 12. This manuscript investigates the impact of this policy on HPV 
vaccination among 13 ̶ 17 year-old female adolescents using National Immunization 
Survey-Teen data 2008 ̶ 2012. 
Drawing on the data from the 2008-2012 National Immunization Survey (NIS-
Teen), we compared the difference in proportions of females who have been vaccinated 
before and after the policy (n=2,327). Using difference-in-difference estimation, we 
explored the change in vaccination rates before and after the policy implementation in 
Louisiana compared to Alabama and Mississippi, who did not have such a policy in 
place. 
The difference-in-differences estimate for HPV vaccination was not significant.  
Physician recommendation for HPV vaccine recommendation was strongly associated 
with vaccination for females in Louisiana and Alabama (aOR=7.74; 95% CI: 5.22 ̶ 11.5) 
and for those in Louisiana and Mississippi (aOR=7.05; 95% CI: 4.6 ̶ 10.5). Compared to 
the proportion of female adolescents who had received a physician recommendation in 
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Alabama or Mississippi, the proportion in Louisiana did not increase significantly in the 
post-policy period.    
HPV vaccination rates did not increase significantly in Louisiana compared to 
Alabama or Mississippi following the implementation of the policy. Despite Louisiana’s 
policy, physician recommendation remains the factor most strongly associated with HPV 
vaccination. HPV vaccine awareness did not necessarily result in HPV vaccination.   
Background 
The Food and Drug Administration has licensed two HPV preventative vaccines 
since 2014 (U.S. Food and Drug Administration, 2014). The Advisory Committee on 
Immunization Practices (ACIP) recommends routine HPV immunization for 11 ̶ 12 year-
olds (Centers for Disease Control and Prevention, 2012). HPV vaccination rates remain 
well below the 80% coverage of Healthy People 2020 (U.S. Department of Health and 
Human Services, 2014). In 2014, only 60% of females aged 13 ̶ 17 years had initiated, 
and 39.7% of females had completed the HPV vaccine series (Reagan-Steiner et al., 
2015). Among the males in the same age-group, while 41.7% had initiated, only 21.6% 
had completed the vaccine series (Reagan-Steiner et al., 2015).  
In March 2008, House Bill 359 (HB359) was introduced to Louisiana’s House of 
Representatives. In June 2008, it became Act 210 without the governor’s signature 
(Louisiana State Legislature, 2008). Act 210 requires the Department of Health and 
Hospitals to provide HPV/HPV vaccine information to the Department of Education, 
which would provide this information to the city, parish, and school boards. School 
boards are required to distribute the information to parents or guardian of students in 
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grades 6 ̶ 12. The HPV/HPV vaccine information must include a form requesting parental 
permission to provide HPV information to students directly (Louisiana State Legislature, 
2008). When it was first introduced, Louisiana’s HB359 would apply to female students 
in sixth grade, but it later included students of both genders in grades six through twelve 
(Louisiana State Legislature, 2008). 
Several states have passed bills requiring HPV-related education and HPV 
vaccine availability for adolescents, or parents, or both. Indiana, Utah, Iowa, New Jersey, 
and Washington took the lead on HPV and HPV vaccine awareness legislatures in the 
2006 ̶ 2007 period (National Conference of States Legislatures, 2015). Since 2008, 
several states have considered HPV vaccine awareness policies, including Kentucky and 
Missouri. While several states have implemented policies aimed at increasing HPV 
vaccine awareness, the effectiveness of these policies at increasing HPV vaccination has 
not been evaluated. This study investigates the impact of Louisiana’s HPV and HPV 
vaccine awareness policy on HPV vaccination among 13 ̶ 17 year-old females using 
National Immunization Survey-Teen (NIS-Teen) data 2008 ̶ 2012.  
Methods 
NIS-Teen Survey 
The purpose of the National Immunization Survey (NIS) is to estimate 
vaccination coverage among children 19 to 35 months old. The NIS-Teen is a NIS 
appended survey, which uses random digit dialing telephone survey of households to 
provide an estimation of vaccination coverage among adolescents (Curtin, Lester et al., 
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2013). NIS-Teen data collection is conducted in two stages: a household telephone 
survey that collects information on immunization status of adolescents from the teen’s 
parent or guardian, along with a permission request to contact the adolescent’s healthcare 
provider; and an immunization questionnaire mailed to teen’s healthcare providers 
(Curtin, Lester et al., 2013). NIS-Teens’ detailed survey methodology has been published 
elsewhere (National Centers for Health Statistics, 2013). 
Study Design 
The current study analyzed the effects of a natural experiment (i.e. 
implementation of a HPV vaccination law in Louisiana) using a pre-post implementation 
design (difference-in-differences), with the state of Alabama and Mississippi as 
comparison groups. A natural experiment is one in which an intervention varies through 
the natural occurrence of an event that is exogenous to the outcome of interest (Petticrew 
et al., 2005; Remler & Van Ryzin, 2011). It allows comparisons between the group that 
experiences the event and the group that did not (Petticrew et al., 2005; Remler & Van 
Ryzin, 2011). The different HPV vaccine policies implemented in the southern Black 
Belt states are an excellent source of natural variation.  
Although several methods have been used to assess the effectiveness of public 
health policies, difference-in-differences is among the most widely used methods (Mason 
et al., 2015; Patel et al., 2014; Rajaram et al., 2014). Difference-in-Differences estimates 
the treatment effect on the treated group by subtracting the change in the outcome for the 
comparison group before and after the treatment from the change in the outcome for the 
treatment group before and after the treatment (Descy & Tessaring, 2004; Meyer, 1995b). 
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This approach controls for unobserved differences that may bias the treatment effect 
estimate (Descy & Tessaring, 2004; Meyer, 1995b).    
Treatment and Comparison States 
Louisiana is located in the Black Belt, which is a part of the South. Other Black 
Belt states includes Florida, Georgia, North Carolina, South Carolina, Virginia, Alabama, 
Mississippi, Tennessee, Arkansas, and Texas. The Black Belt is known for its high 
poverty, high unemployment rates, low educational attainment, high rates of health 
disparities, and high concentration of individuals of African descent are characteristic of 
this sub-region (Wimberly & Morris, 1997). For this analysis, the control state and the 
comparison should be very similar except in HPV policies and other policies that may 
influence HPV vaccinations Black Belt states that are in geographic proximity with 
Louisiana include Texas, Arkansas, Mississippi and Alabama. 
In 2007, Texas enacted a HPV vaccine mandate by executive order, but the 
mandate was later overturned by legislature. Additionally, Texas has enacted a bill 
requiring the Department of Health to distribute HPV-related educational materials 
(National Conference of States Legislatures, 2015). Therefore, Texas could not serve as a 
comparison state. In 2010, the Affordable Care Act was signed into law by President 
Obama. Initially, it would initially require the expansion of Medicaid, but the Supreme 
Court has made the Medicaid expansion an option for states. In the Black Belt region, 
only Arkansas implemented the expansion, which increased Medicaid coverage for 
children (Rudowitz, Artiga, & Musumeci, 2014). As a result, Arkansas was not chosen as 
a comparison state for Louisiana. Neither Alabama nor Mississippi has enacted bills 
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requiring the distribution of HPV-related education materials or HPV vaccinations for 
girls in the sixth grade.   
Louisiana and Alabama are separated by the state of Mississippi. For the 2007 ̶ 
2010 period, the average median household income was $41,438 in Louisiana, $36,697 in 
Mississippi, and $41,911 in Alabama (U.S. Census Bureau, 2013a). During the 2007–
2012 period, the average graduation rate among 18 ̶ 24 year-olds was 79% in Louisiana, 
79.4% in Mississippi, and 82.3% in Alabama (U.S. Census Bureau, 2014a).  During the 
same time period, the average poverty rate was 18.7% in Louisiana, 20.9% in 
Mississippi, and 15.7 in Alabama (U.S. Census Bureau, 2014b). Although the high school 
graduation rates are more similar between Louisiana and Mississippi, the income and 
poverty gap is wider for Louisiana and Mississippi. Due to their similarities with 
Louisiana, both states were chosen as comparison states.  
Sample and Population 
Although Louisiana’s policy became effective in June 2008 (National Conference 
of States Legislatures, 2015), the school parishes or boards were responsible for its 
implementation (Louisiana State Legislature, 2008). As a result, the implementation did 
not occur in the same year all parishes and school boards. The majority of parishes and 
school boards did not implement the policy until 2010 (Louisiana Board of Education 
representative, Personal Communication, March 7, 2014). The pre-policy period was 
2008 ̶ 2009; the implementation year was 2010; and the post-policy period was 2011 ̶ 
2012. The response rate for the telephone interview was 85.2% for 2008, 85.4% in 2010, 
84.7% in 2011, and 75.5% in 2012 (Centers for Disease Control and Prevention & 
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National Centers for Health Statistics, 2013). The sample included females aged 13 ̶ 17 
years whose parents or guardians responded to questions about HPV vaccination from the 
telephone survey.  For Louisiana and Alabama 2,630 females and for Louisiana and 
Mississippi 2,826 females provided a response.   
Variables  
Maternal education, maternal marital status, household income, teen’s 
race/ethnicity, age, gender, state of residence, health insurance status, healthcare visits in 
the past 12 months, and HPV vaccination status were included in the analysis. Teens who 
had received at least one dose were classified as vaccinated. HPV vaccination history 
from the telephone rather than from the healthcare provider questionnaire were used. The 
kappa agreement between HPV vaccination status from the household survey and HPV 
vaccination status from provider was 92.5%.   
Statistical Analysis  
We performed weighted Pearson’s chi-square test to investigate the variation in 
demographic factors between Louisiana and Alabama and between Louisiana and 
Alabama. Additionally, we estimated a difference-in-differences model to quantify the 
difference in the change in vaccination rates between Louisiana and Alabama, and 
between Louisiana and Mississippi before and after the policy implementation. 
Subsequently, a logistic regression analysis with ‘policy’ and ‘period’ interaction was 
performed to estimate the difference-in-differences in HPV vaccination among females 
living in Louisiana or Alabama in order to control for demographic variables using the 
following model:  
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Logit (Pr(Y =1|period, treatment, period*treatment, age…… physician 
recommendation)) =  + 1*state + 2 *period+ 3 *(period * state) + X (1)  
Y is HPV vaccination (1 = yes/0 = no), and X is a vector of control variables that 
included age, medical visits, maternal education, maternal income, and physician 
recommendation. Two logistic regression models were built to estimate difference-in-
differences in HPV vaccination while controlling for demographic factors. The first 
model included the policy, the period, and the policy and period interaction variables.  
For the second model, the demographic variables were added to the first model. To 
estimate difference-in-differences in physician recommendation, two logistic regression 
models were built using the following model:  
Logit (Pr(Y =1|period, treatment, period*treatment, age……and maternal 
income)) =  + 1*state + 2 *period+ 3 *(period * state) + X (2)  
Y is HPV vaccine recommendation from a physician (1 = yes/0 = no), and X is a 
vector of control variables. A linktest was performed to assess the fit of the model. A p-
value <0.05 was used as the threshold for statistical significance. All statistical analyses 
were performed using STATA 13 (StataCorp, 2013), and all estimates were weighted to 
females aged 13-17 in the relevant states and years included in each analysis.   
Results 
HPV Vaccination 
In 2008, 28.8% of adolescent females in Louisiana, 25.7% in Alabama, and 
18.5% in Mississippi received at least one dose of the HPV vaccine. Vaccination rate 
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increased to 36.7% in Louisiana, 37.7% in Alabama, and 20.1% in Mississippi in 2009.  
In 2010, vaccination rates increased to 39.9% in Louisiana, remained constant in 
Alabama (37.7%), and increased to 23.2% in Mississippi.  Vaccination rates increased to 
50.4% in Louisiana, 42.2% in Alabama, and 26.5% in Mississippi in 2011.  In 2012, 
vaccination rates increased to 53.6% in Louisiana, 42.7% in Alabama, and 38.9% in 
Mississippi.  While the largest increase in vaccination rates in Louisiana was from 2010 
to 2011 (39.9  50.4%), Alabama’s largest increase was from 2008 to 2009 (25.7  37.7%).  
For Mississippi, the greatest increase in vaccination was from 2011 to 2012 (26.5  38.9%) 
(Figure 1).   
[Figure 1 Here] 
The difference-in-differences in vaccination rates between Louisiana and 
Alabama and between Louisiana and Mississippi was not significant (Table 1). In the pre-
policy period, females in Louisiana and Alabama differed by insurance coverage history 
and household income (Table 2), whereas females in Louisiana and Mississippi differed 
by vaccination status, insurance coverage history, vaccine recommendation status, age at 
last medical check-up, and 11-12-year-old medical check-up status (Table 2). In the post-
policy period, females in Louisiana and Alabama differed only in vaccination status 
while females in Louisiana and Mississippi differed by vaccination status, race/ethnicity, 
number of medical visits, history of insurance coverage, vaccine recommendation status, 
age at last medical visits, and 11−12-year-old medical check-up status (Table 3). 
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[Table 1 Here] 
[Tables 2 & 3 Here] 
 
For the logistic regression model fitting, the linktest results were not significant 
for any of the models, which indicated that our models ware properly specified. For 
females in Louisiana and Alabama, the first logistic regression model indicated that in the 
post-policy period, female adolescents had higher odds of taking the vaccine than in the 
pre-policy period (aOR=1.60; 95%CI: 1.16  2.6). The period and the interaction variables 
were not significant (Table 4). In the second model, HPV vaccine recommendation was 
strongly associated with vaccination (aOR=7.74; 95%CI: 5.22  11.5). Black adolescent 
females had lower odds of being vaccinated compared to whites (aOR= 0.58, 95%CI: 
0.37  0.90). Those with family income below the federal poverty level had higher odds of 
being vaccinated (aOR= 2.44; 95%CI: 1.25  4.75) compared to those with a family 
income of $75,000 or above. Additionally, teens who had seven or more medical visits 
had higher odds of vaccination (aOR=2.84; 95%CI: 1.32  2.85) compared to those who 
had three or fewer visits (Table 4). For Louisiana and Mississippi, the first model 
indicates that females in Louisiana had higher odds of vaccination compared to those in 
Alabama (aOR=2.01; 95%CI: 1.47-2.8) and females from both states had higher odds of 
vaccination in the post-policy period (aOR=2.0 95%CI: 1.4-2.77), but the interaction 
term was not significant (Table 4).  In the second model, HPV vaccine recommendation 
was the only factor associated with vaccination (aOR=7.05; 95%CI: 4.6  10.7) (Table 4). 
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[Table 4 Here] 
Physician Recommendation 
In 2008, 38.7% of adolescent females in Louisiana received a HPV vaccine 
recommendation from their healthcare provider compared to 42.5% in Alabama, and 
28.5% in Mississippi (Figure 2). HPV vaccine recommendation increased to 55.8% in 
Louisiana, 50.0% in Alabama, and 34.5% in Mississippi in 2009. Vaccine 
recommendation decreased in all three states in 2010.  The rates dropped to 44.6% in 
Louisiana, 49.5% in Alabama, and 29.7% in Mississippi. In 2011, vaccine 
recommendation increased to 51.9% in Louisiana, 57.1% in Alabama, and 40.8% in 
Mississippi. It increased to 59.5% in Louisiana, decreased to 53.1% in Alabama, and 
increased to 40.8% in Mississippi in 2012. The difference-in-differences in vaccine 
recommendation was not significant in the Louisiana-Alabama comparison or in the 
Louisiana-Mississippi comparison (Table 5).   
[Figure 1 Here] 
[Table 5 Here] 
 
For the logistic regression model fitting, the linktest was not significant for any 
the models, which indicated that our models are properly specified.   For Louisiana and 
Alabama, the first logistic regression model estimating the difference-in-differences in 
physician recommendation, the odds of receiving a physician recommendation were 
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higher in the post- compared to the pre-policy period (aOR= 1.44; 95% CI: 1.06  1.95) 
(Table 6). The policy and the interaction variables were not significant. In the second 
model, females whose mother had some college education (aOR= 1.95; 95%CI: 1.05  
3.60) and were college graduates (aOR= 2.80; 95% CI: 1.47  5.35) had higher odds of 
receiving HPV vaccine recommendation. Also, adolescent females who had seven or 
more medical visits had lower odds of receiving physician recommendation (aOR= 0.40; 
95%CI: 0.21  0.78).  Also, those who did not have their 11  12-year-old medical check-up 
had lower odds of receiving vaccine recommendation (aOR= 0.52; 95% CI: 0.30  0.90) 
(Table 6).  
 For Louisiana and Mississippi, the first logistic regression showed that females in 
Louisiana had higher odds of receiving a physician recommendation for the vaccine 
(aOR= 1.93; 95% CI: 1.45  2.56) (Table 6). Females had higher odds of receiving 
physician recommendation in the post- compared to the pre-policy period (aOR= 1.80; 
95% CI: 1.035  2.42). The interaction term was not significant. In the second model, 
females in Louisiana had higher odds of receiving the recommendation compared to 
those in Mississippi (aOR= 1.81; 95% CI: 1.05  3.1). The interaction term was not 
significant. Females whose mother had some college education (aOR= 2.1; 95%CI: 1.07  
4.1) had higher odds of receiving HPV vaccine recommendation. Those who did not have 
their 11  12-year-old medical check-up had lower odds of receiving a HPV vaccine 
recommendation (aOR= 0.48; 95% CI: 0.28  0.82) (Table 6).  
 
[Table 6 Here] 
77 
 
Discussion 
HPV Vaccination 
The difference-in-differences in HPV vaccination rates between Louisiana and 
both comparison states was not significant, suggesting that factors other than Louisiana’s 
policy contributed to the increase in vaccination rates observed in Louisiana.  The policy 
and period interaction term was not significant in the logistic regression models, which 
indicated that Louisiana’s policy did not result in a significant increase in vaccination.   
In agreement with previous studies, we found physician recommendation to be a 
major determinant of HPV vaccination (Reiter, Katz, & Paskett, 2013; Vadaparampil et 
al., 2014). Additionally, in Louisiana and Alabama teens living below the poverty level 
had higher odds of being vaccinated, and the odds of vaccination did not differ by health 
insurance status since teens were 11 years of age. A previous study has reported similar 
vaccination rates among uninsured and insured teens (Pierre-Victor, Mukherjee, Bahelah, 
& Madhivanan, 2014), and another study has reported higher vaccination rates among 
those living below the federal poverty level (Reagan-Steiner et al., 2015). Moreover, in 
Louisiana and Alabama, Black females had lower odds of being vaccinated. This finding 
contradicts the recent findings reported by Reagan-Steiner and colleagues (Reagan-
Steiner et al., 2015), but are in agreement with previous studies (Niccolai, Mehta, & 
Hadler, 2011; Stokley, Dorell, & Yankey, 2009). Lack of access to care, especially for 
those living in rural areas, may contribute to the lower odds of vaccination among Blacks.  
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Vaccine Recommendation 
The difference-in-differences in vaccine recommendation rates and vaccination 
rates between Louisiana and both comparison states was not significant. These findings 
suggest that the implementation of the policy did not lead to an increase in vaccine 
recommendation. HPV vaccine awareness was not captured in every survey year and 
therefore could not be included in the analysis. Females who did not have their 11–12-
year old check-up had lower odds of receiving a HPV vaccine recommendation.  
Adolescent females whose mother had some college education and beyond had higher 
odds of receiving a HPV vaccine recommendation or to recall having received a HPV 
vaccine recommendation even though their odds of vaccination were not significantly 
greater. The higher odds for physician recommendation may result from physicians 
assuming that mothers with a college education would be more knowledgeable about the 
vaccine and therefore more likely to respond positively to the recommendation for the 
vaccine.    
Socio-political Context 
Contrary to HPV vaccine mandates, vaccine awareness policies were not 
surrounded by controversy (Laugesen et al., 2014) nor receive negative news coverage 
(Casciotti et al., 2014). Even when parents and adolescents are aware of HPV vaccine, 
structural barriers  including lack of transportation, out-of-pocket cost, parental consent, 
safety concerns, and parental sexual promiscuity concerns  may hinder adolescents from 
taking the vaccine (Kaplan, 2010). Additionally, vaccine awareness must be followed be 
vaccine recommendation in order for decision-making to occur.    
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Limitations and Strengths 
The present study had several limitations. The major limitation of the research is 
the use of pooled cross-sectional data. Furthermore, difference-in-differences assumes 
that time-varying unmeasured characteristics are constant over the time periods in the 
treatment state and do not correlate with HPV vaccinations. We verified that no 
significant changes took place for some characteristics not measured in the dataset such 
as bills directly impacting Medicaid SCHIP eligibility, and Medicaid expansion under the 
Affordable Care Act. However, the assumption that time-varying unmeasured 
characteristics are constant over the time periods could not be tested fully. Additionally, 
this study uses pooled cross-sectional rather than longitudinal data. Moreover, while the 
policy and the control states are similar, they are not identical.   
Despite these limitations, this study evaluated an important policy that could serve 
as a model for other states in the Black Belt and had several strengths. First, it used data 
from a nationally representative sample of non-institutionalized U.S. population. 
Additionally, this study is among the first few to assess the impact of Louisiana’s policy 
requiring that schools sent HPV/HPV vaccine information to parents of students in grades 
6  12 on HPV vaccination among13  17 year-old females. Furthermore, a potential pitfall 
in policy analysis is “policy endogeneity,” which would occur, if Louisiana’s policy was 
adopted to increase HPV vaccination due to low HPV vaccination. There was no 
evidence that Louisiana adopted its policy due to low HPV vaccination.   
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Conclusion  
The policy did not lead to HPV vaccination. Nevertheless, the importance of the 
delivery of uniform and accurate HPV vaccine information should not be ignored, as the 
information prepares parents and adolescents for the physician recommendation.  Despite 
HPV vaccine awareness among parents, physician recommendation remains the key 
predictor of HPV vaccination.  
Since provider recommendation plays a vital role in HPV vaccination, we must 
continue policy and educational efforts to not only deliver uniform and accurate HPV 
vaccine information in order to prepare parents and adolescents for the vaccine 
recommendation but also to facilitate physician recommendation.  In private practice 
settings, the nurse and the physician assistant interact more with the patient than the 
physician. Therefore, they are instrumental in patient education and decision-making.  
They are in a position to educate the patients about HPV and the vaccine prior to their 
meeting with the physician and assist them in the decision-making following the 
physician recommendation. In other settings, healthcare providers should continue to 
decrease missed opportunities for HPV vaccination. Previous studies have identified 
school-based health centers (SBHCs) as a setting with a great potential to increase HPV 
vaccination (Golden et al., 2014; Kaplan, 2010), particularly for adolescents in rural areas 
and those who may lack access. SHBCs can boost HPV vaccinations by sending parents 
educational materials regarding all recommended vaccines along with immunization 
consent forms. 
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Figure 1. HPV vaccination trends in Louisiana, Alabama, and Mississippi 2008-
2012 
 
*Policy implementation year 
1 1 dose of HPV vaccine 
 
 
Table 1. Difference-in-differences in HPV vaccination rates in Louisiana and 
Alabama, Louisiana and Mississippi 
N= 2,162 Pre-policy Period  
(2008-09) 
Post-policy period 
 (2011-12) 
Difference 
Louisiana 0.325 0.519 0.194** 
Alabama 0.317 0.425 0.108 
DiD     0.086 
N= 2,275    
Louisiana 0.325 0.519 0.194** 
Mississippi 0.193 0.323 0.13 
DiD   0.064 
* p<0.05; ** p<0.01 
DiD= difference-in-differences 
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Table 2. Difference in selected demographic characteristics in Louisiana and 
Alabama, and in Louisiana and Mississippi, pre-policy period 
Characteristics 
Louisiana 
(n=552 ) 
Alabama 
(n=525 ) 
 Mississippi 
(n=626 ) 
 
%  (95% CI) % (95% CI) p-
valu
e 
%(95% CI) p-
value 
Vaccinated 
 
 0.46  0.01 
No 71.2 (65.2-
76.5) 
74.3 (68.0-
80.0) 
 81.5(75.8-86.1)  
Yes 28.8 (23.5-
34.8) 
25.7 (20.3-
32.0) 
 18.5 (13.9-
24.1) 
 
Race and ethnicity 
 
 0.19  0.83 
Hispanic 2.1 (1.0-4.1) 2.6 (1.1-6.0)  2.5 (1.4-4.5)  
Non-Hispanic White 52.0 (45.4-
58.5) 
61.6 (54.4-
68.4) 
 48.4 (42.1-
54.8) 
 
Non-Hispanic Black 42.5 (35.9-
49.3) 
33.4 (26.8-
40.7) 
 45.7 (39.5-
52.3) 
 
Other 3.5 (1.8-6.3) 2.4 (0.93-
6.0) 
 3.3 (1.8-6.0)  
Teen's age 
 
 0.54  0.9 
13-15years 63.2 (56.9-
69.0) 
60.3(53.3-
66.9) 
 62.6 (56.2-
68.6) 
 
16-17 years 36.8 (31.0-
43.2) 
39.7 (33.1-
46.7) 
 37.4 (31.4-
43.8) 
 
No. of medical visits 
last  year   
 
 0.97  0.11 
1 to 3 76.7 (70.9-
81.6) 
76.0 (69.7-
81.3) 
 78.4 (72.5-
83.3) 
 
4 to 6 21.0 (16.2-
26.7) 
21.8 (16.7-
28.0) 
 16.4 (12.2-
21.8) 
 
7 to 9 2.3 (1.2-4.5) 2.2 (0.92-
5.1) 
 5.2 (2.9-9.2)  
Ever been uninsured 
since age 11  
 
 0.00
1 
 0.02
2 
Yes 4.3 (2.5-7.4) 13.0 (8.5-
19.4) 
 9.6 (6.2-14.8)  
No 95.7 (92.6-
97.5) 
87.0 (80.6-
91.5) 
 90.4 (85.2-
93.8) 
 
 HPV vaccine 
recommendation 
 
 0.47  0.01
9 
No 61.3 (54.9-
67.2) 
57.9 (51.1-
64.4) 
 71.5 (65.3-
77.0) 
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Yes 38.7 (32.8-
45.1) 
42.1 (35.6-
48.9) 
 28.5 (23.0-
34.7) 
 
Age at last 
medical visits 
   
0.71  0.01
4 
less than 11 years 4.9 (2.9-8.1) 4.1 (1.8-9.0)  10.8 (7.2-15.8)  
11 years or older 95.1 (91.9-
97.1) 
95.9 (91.0-
98.2) 
 89.2 (84.2-
92.8) 
 
Teen had 11-12 
year-old medical 
check-up? 
 
 0.76  0.03
6 
No 16.1 (11.1-
22.7) 
17.3 (12.4-
23.6) 
 25.7 (19.5-
33.1) 
 
Yes 83.9 (77.3-
88.9) 
82.7 (76.4-
87.6) 
 74.3 (66.9-
80.5) 
 
Marital status of mother 
 
0.61  0.81 
Married 61.1 (48.6-
72.3) 
65.9 (50.7-
78.4) 
 63.0 (51.5-
73.2) 
 
Not married 38.9 (27.7-
51.4) 
34.1 (21.6-
49.0) 
 37.0 (26.8-
48.4) 
 
Mother's education level 
 
0.13  0.12 
Less than high 
school 
13.7 (9.5-19.3) 12.7 (8.9-
17.9) 
 17.4 (12.7-
23.3) 
 
High school 39.0 (32.6-
45.8) 
30.1 (23.7-
37.3) 
 
29.5 (23.8-
36.0) 
 
Some College 27.7 (22.5-
33.5) 
29.5 (23.7-
36.2) 
 27.4 (22.2-
33.2) 
 
college graduate 19.7 (15.6-
24.5) 
27.7 (22.4-
33.6) 
 25.8 (20.9-
31.3) 
 
Household income 
 
 0.04
1 
 
0.83 
Above poverty 
>$75,000 
25.3 (20.5-
30.8) 
35.7 (29.7-
42.2) 
 24.2 (19.4-
29.7) 
 
Above poverty  
<= $75,000 
45.1 (38.8-
51.6) 
46.0 (38.3-
52.0) 
 42.5 (36.4-
48.9) 
 
Below poverty level 25.0 (19.0-
32.0) 
15.9 (11.0-
22.5) 
 28.4 (22.5-
35.0) 
 
Unknown 4.6 (2.8-7.3) 3.3 (1.6-7.0)  4.9 (2.9-8.1)  
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Table 3. Difference in selected demographic characteristics in Louisiana and 
Alabama, in Louisiana and Mississippi, post-policy period 
Characteristics Louisiana 
(n=598 ) 
Alabama 
(n=487 ) 
 Mississippi 
(n=529 ) 
 
 %(95% CI)  %(95% CI) p-
value 
 %(95% CI) p-
value 
Vaccinated 
 
 0.03  0.000
1 
No 52.4 (48.1-
56.6) 
59.2 (54.5-
63.7) 
 70.8(66.8-74.6)  
Yes 47.6 (43.4-
51.9) 
40.8 (36.3-
45.5) 
 29.2 (25.4-
33.2) 
 
Race and ethnicity 
 
 0.2  0.006 
Hispanic 4.6 (3.2-6.6) 4.6 (3.0-6.9)  2.2 (1.3-3.7)  
Non-Hispanic 
White 
51.3 (47.2-
55.4) 
57.7 (53.1-
62.1) 
 48.2 (44.0-
52.5) 
 
Non-Hispanic 
Black 
38.5 (34.4-
42.8) 
33.3 (28.9-
38.0) 
 46.3 (42.0-
50.6) 
 
Other 5.5 (3.9-7.8) 4.5(3.2-6.2)  3.3 (2.0-5.2)  
Teen's age 
 
 0.39  0.88 
13-15years 61.3 (57.2-
65.3) 
58.7 (54.3-
63.0) 
 60.9 (56.6-
64.9) 
 
16-17 years 38.7 (34.7-
42.8) 
41.3 (37.0-
45.7) 
 39.1 (35.1-
43.4) 
 
No. of medical 
visits last year   
 
 0.09  0.039 
1 to 3 72.5 (68.5-
76.1) 
75.9 (72.0-
79.4) 
 77.6 (74.0-
80.9) 
 
4 to 6 20.8 (17.5-
24.5) 
30.2 (16.9-
34.0) 
 18.6 (15.6-
22.1) 
 
7 to 9 6.7 (4.8-9.2) 3.9 (2.7-5.5)  3.7 (2.6-5.4)  
Ever been 
uninsured since 
age 11  
 
 0.27  0.02 
Yes 5.7 (3.8-8.5) 7.8 (5.3-11.4)  10.4 (7.6-14.0)  
No 94.3 (91.5-
96.2) 
92.2 (88.6-
94.7) 
 89.6 (86.0-
92.4) 
 
 HPV vaccine 
recommendation 
 
 0.68  0.000
1 
No 48.1(43.0-
52.3) 
46.8 (42.3-
51.3) 
 59.9 (55.7-
64.0) 
 
Yes 51.9 (47.7-
56.1) 
53.2 (48.7-
57.7) 
 40.1 (36.0-
44.4) 
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Age at last 
medical visits 
 
 0.23  0.000
1 
Less than 11 years 3.2 (2.3-4.6) 4.5 (3.0-6.7)  8.2 (6.3-10.5)  
11 years or older 96.8 (95.4-
97.7) 
95.5 (93.3-
97.5) 
 91.8 (89.5-
93.7) 
 
Teen had 11-12 
year-old medical 
check-up? 
 
 0.24  0.03 
No 11.7 (8.9-15.2) 9.1 (6.7-12.4)  11.7 (8.9-15.2)  
Yes 88.3 (84.8-
91.1) 
90.9 (87.6-
93.3) 
 88.3 (84.8-
91.1) 
 
Marital status of 
mother 
 
 0.78  0.59 
Married 58.0 (53.8-
62.1) 
58.9 (54.3-
63.3) 
 56.3 (51.9-
60.6) 
 
Not married 42.0 (37.9-
46.3) 
41.1 (36.7-
45.7) 
 43.7 (39.4-
48.1) 
 
Mother's 
education level 
 
 0.21  0.075 
Less than high 
school 
14.0 (11.0-
17.5) 
14.3 (11.4-
17.9) 
 12.4 (9.6-15.7)  
High school 33.5 (29.5-
37.8) 
28.0 (23.9-
32.5) 
 27.6 (23.8-
31.8) 
 
Some College 25.2 (22.11-
28.6) 
25.7 (22.3-
29.7) 
 30.8 (27.0-
34.9) 
 
College graduate 27.3 (24.1-
30.7) 
32.0 (28.4-
35.9) 
 29.2 (25.8-
32.9) 
 
Household  
income 
 
 0.23  0.051 
Above poverty 
>$75,000 
28.0 (24.9-
31.3) 
29.6 (26.1-
33.2) 
 21.9 (19.1-
25.0) 
 
Above poverty  
<= $75,000 
39.0 (35.0-
43.0) 
37.0 (32.9-
41.4) 
 39.2 (35.1-
43.4) 
 
Below poverty 
level 
28.7 (24.6-
33.0) 
26.4 (22.3-
30.9) 
 34.6 (30.3-
39.1) 
 
Unknown 4.4 (3.2-6.1) 7.0 (5.1-9.5)  4.3 (3.1-6.0)  
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Table 4. Odds ratios for HPV vaccination according to selected characteristics, 
Louisiana and Alabama, and Louisiana and Mississippi 
 Louisiana and Alabama Louisiana and Mississippi 
Characteristi
cs 
Model 1 
(n=2162) 
Model 2 
(n=949) 
Model 1 
(n=2,305) 
Model 2 
(n=936) 
aOR (95%CI) aOR (95%CI) aOR (95%CI) aOR (95%CI) 
Policy 
implemented   
  
No Ref. Ref. Ref. Ref. 
Yes 1.04 (0.77-
1.4) 0.80 (0.44-1.4) 
2.01 (1.47-
2.8)*** 
1.50 (0.81-2.8) 
Period     
Pre Ref. Ref. Ref. Ref. 
Post 1.60 (1.2-
2.6)** 1.21 (0.73-2.0) 
2.0 (1.4-
2.77)*** 
1.46 (0.81-2.6) 
Interaction 
term   
  
Policy*period 1.41 (0.90-
2.2) 1.80 (0.86-3.8) 
1.12 (0.72-1.8) 1.41 (0.64-3.1) 
 HPV vaccine 
recommendati
on 
  
  
No  Ref.  Ref. 
Yes 
 
7.74(5.22-
15)*** 
 7.05 (4.6-
10.7)*** 
Race and 
ethnicity   
  
Non-Hispanic 
White  Ref. 
 Ref. 
Hispanic  1.08 (0.49-2.4)  1.37 (0.45-4.1) 
Non-Hispanic 
Black  
0.58 (0.37-
0.9)* 
 0.68 (0.43-1.1) 
Other  1.21 (0.50-2.9)  1.62 (0.50-5.3) 
Mother's 
education 
level 
  
  
Less than high 
school  Ref. 
 Ref. 
High school  0.99 (0.51-1.9)  1.13(0.55-2.3) 
Some College  1.5(0.78-2.9)  1.36 (0.66-2.8) 
College 
graduate  1.31 (0.64-2.6) 
 1.45 (0.65-3.3) 
90 
 
Household 
income   
  
Above poverty 
>$75,000  Ref. 
 Ref. 
Above poverty 
<= $75,000  1.55 (0.96-2.5) 
 1.29 (0.77-2.2) 
Below poverty 
level  
2.44 (1.25-
4.8)** 
 1.72 (0.78-3.8) 
Unknown  1.23 (0.53-2.9)  2.6 (0.91-5.6) 
No. of medical 
visits  last year    
  
1 to 3  Ref.  Ref. 
4 to 6  1.39 (0.90-2.1)  1.30 (0.80-2.1) 
7 to 9 
 
2.84 (1.32-
2.9)** 
 2.24 (0.97-5.2) 
Ever been 
uninsured 
since age 11  
  
  
Yes  Ref.  Ref. 
No  1.41 (0.75-2.7)  1.64 (0.78-3.4) 
Mother's 
marital status   
  
Married  Ref.  Ref. 
Not married  1.26 (0.82-1.9)  1.11 (0.71-1.7) 
Teen's age     
13-15 years  Ref.  Ref. 
16-17 years  1.08 (0.76-1.5)  0.95 (0.65-1.4) 
Teen had 11-
12 year-old 
check-up? 
  
  
Yes  Ref.  Ref. 
No  0.91 (0.51-1.6)  1.2 (0.64-2.2) 
* p<0.05; ** p<0.01; *** p<0.001 
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Figure 4. Physician recommendation trends in Louisiana and Alabama, and 
Mississippi, 2008-2012 
 
*Policy implementation year  
 
Table 5. Difference-in-differences estimates for physician recommendation 
proportions in Louisiana and Alabama, Louisiana and Mississippi 
N= 2,218 Pre-policy period 
(2008-09) 
Post-policy period 
(2011-12) 
Difference 
Louisiana 0.47 0.557 0.087 
Alabama 0.461 0.551 0.09 
DiD   0.003 
N= 2,343    
Louisiana 0.47 0.557 0.087*** 
Mississippi 0.315 0.454 0.139*** 
DiD   0.052 
* p<0.05; ** p<0.01; *** p<0.001 
DiD= difference-in-differences 
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Table 6. Odds ratios for HPV vaccine recommendation according to selected 
characteristics, Louisiana and Alabama, Louisiana and Mississippi 
 Louisiana and Alabama Louisiana and Mississippi 
Characteristics Model 1 
(N=2,227) 
Model 2 ( 
N=1,007) 
 Model 1 
(N=2,375) 
Model 2 
(N=998) 
aOR 
(95%CI) 
aOR 
(95%CI) 
aOR 
(95%CI) 
aOR 
(95%CI) 
Policy implemented 
 
   
No Ref. Ref. Ref. Ref. 
Yes 1.04 (0.78-
1.38) 
1.11 (0.66-
1.87) 
1.93 (1.45-
2.6)*** 
1.81 (1.05-
3.1)* 
Period 
 
   
Pre Ref. Ref. Ref. Ref. 
Post 1.44 (1.06-
1.95)* 
1.23(0.76-
2.0) 
1.80 (1.35-
2.4)*** 
1.34 (0.81-
2.2) 
Interaction term 
 
   
Policy*period 0.99 (0.64-
1.51) 
1.09 (0.56-
2.1) 
0.79 (0.52-
1.2) 
0.99 (0.49-
2.0) 
Race and ethnicity 
 
   
Non-Hispanic White  Ref.  Ref. 
Hispanic  1.71(0.71-
4.2) 
 1.10 (0.40-
3.0) 
Non-Hispanic Black  1.05 (0.42-
2.6) 
 0.77 (0.27-
1.3) 
Other  1.49 (0.50-
4.4) 
 1.09 (0.30-
4.0) 
Mother's education 
level 
 
   
Less than high school  Ref.  Ref. 
High school  1.17 (0.64-
2.1) 
 1.13 (0.58-
2.2) 
Some College  1.95 (1.06-
3.6)* 
 2.1 (1.07-
4.1)* 
College graduate  2.80 (1.47-
5.4)** 
 2.3 (1.15-
4.6) 
Household income 
 
   
Above poverty 
>$75,000 
 Ref.  Ref. 
Above poverty  
<= $75,000 
 0.92 (0.60-
1.4) 
 0.90(0.59-
1.4) 
Below poverty level  1.00 (0.56-
1.8) 
 0.76(0.42-
1.4) 
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Unknown  0.99 (0.44-
2.2) 
 1.44 (0.58-
3.5) 
No. of medical visits 
last year 
 
   
1 to 3  Ref.  Ref. 
4 to 6  1.05 (0.71-
1.6) 
 1.12 (0.73-
1.8) 
7 to 9  0.40 (0.21-
0.78)** 
 0.70 (0.35-
1.4) 
Ever been uninsured 
since age 11? 
 
   
Yes  Ref.  Ref. 
No  1.17 (0.64-
1.6) 
 0.93 (0.49-
1.8) 
Mother's marital status 
 
   
Married  Ref.   Ref.  
Not married  1.22 (0.82-
1.8) 
 1.19 (0.78-
1.8) 
Teen's age 
 
   
13-15 years  Ref.   Ref.  
16-17 years  1.04 (0.75-
1.5) 
 1.02 (0.71-
1.5) 
Teen had an 11-12 
year-old check-up? 
 
   
Yes  Ref.  Ref. 
No  0.52 (0.30-
0.90)* 
 0.48 (0.28-
0.8)** 
* p<0.05; ** p<0.01; *** p<0.001 
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Conclusion 
This dissertation sought to provide an estimation of HPV infection in the South as 
compared to the rest of the country to highlight the geographic variation in the United 
States. It was hypothesized that the prevalence of infection from oncogenic HPV types 
would be higher in the South compared to the rest of the country. Although this 
hypothesis was not true for females aged 14  26 years, it was true for females 27  59 years 
old. Moreover, this dissertation sought to evaluate two HPV vaccination policies that 
could serve as prototypes for Southern states. It was hypothesized that HPV vaccination 
rates would be significantly higher in the period after the policy was implemented 
compared with the period preceding the implementation of both Virginia’s and 
Louisiana’s policy. Findings indicated that neither of the two policies have resulted in an 
increase in vaccination rates.   
Several policy analysis frameworks were considered for the theoretical 
framework of the study.  Since the study included a problem identification and a policy 
evaluation components, Lasswell’s Stages Heuristic Public Policy Framework (Lasswell, 
1956) was selected. Lasswell’s theory is among the most well-known public policy 
theories.  He identified four stages in the public policy process: agenda setting, 
formulation, implementation, and evaluation. The agenda setting is the stage in which a 
social problem issue is identified.  In the formulation stage, legislators or policy-makers 
design, introduce, and enact a policy to resolve the social problem previously identified. 
In the implementation stage, the policies are carried out, and in the evaluation stage, the 
impact of the policy is assessed (Lasswell, 1956). Lasswell’s Stages Heuristic Public 
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Policy theory presumes a linear process, thereby oversimplifying the complexity of 
public policy process. This theory has been widely criticized, particularly for its 
presumption of a linear policy process (Sabatier, 2007). Nonetheless, the Lasswell’s 
Stages Heuristic approach encompasses the entire public policy process, which provides a 
wide framework to situate this research.   
The conceptual framework of this dissertation was founded upon the Linking 
Health-related Policy to Health Systems and Outcomes framework (Hardee, Irani, 
Maclnnis, & Hamilton, 2012). The Linking Health-Related Policy to Health Systems and 
Outcomes framework was based on Lasswell’s Stages Heuristic theory and included the 
four stages. Linking Health-Related Policy to Health Systems and Outcomes includes 
seven principal components: enabling environment, health-related policy development, 
health policy and program implementation, health systems and health outcomes, policy 
monitoring, program monitoring, policy and program evaluation (Hardee et al., 2012). 
Linking Health-Related Policy to Health Systems and Outcomes framework considers an 
enabling environment that includes two aspects. The first aspect of the enabling 
environment includes factors such as political stability, government effectiveness, and 
accountability. The second aspect includes political, socio-cultural, and economic factors 
that may facilitate or hinder the policy implementation. It is in such an enabling 
environment that effective public policies can be developed and implemented because it 
dictates not only the development and implementation, but also the impact of the policy. 
The influence of the social, political, and economic factors on the implementation and 
effectiveness of the policy were considered. Additionally, the model considers the 
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problem identification and the health outcome that the policy is intended to influence 
(Hardee et al., 2012). Pertaining to this study, several cancers result from HPV infection, 
but for Southern states, cervical cancer disparities was the central health concern guiding 
HPV vaccination policies. Furthermore, Hardy and colleagues pointed out that the 
evaluation may quantify the adoption of a health behavior by the intended population 
(Hardee et al., 2012).  Relating to this study, HPV vaccination is the healthy behavior 
whose adoption was quantified.   
The dissertation had a few limitations. The first limitation is the use of self-
reported data in all three manuscripts. Self-reported data are subject to recall bias. This 
bias may have decreased the internal validity of the study. The data used for the 
dissertation were also subject to social desirability bias, particularly for sexual risk 
behaviors. Sexual behavior variables were collected using ACASI questionnaires rather 
than face-to-face interviews. ACASI minimizes social desirability bias. The residual 
desirability bias may have resulted in an underrepresentation of sexual risk behaviors, 
thereby reducing study internal validity. Regarding the policy analysis component, 
although the comparison states share regional characteristics with the policy or treatment 
states, they were not identical. Moreover, the collection of some variables previously 
included the NIS-Teen discontinued after 2009.  As a result, they could not be included in 
the policy analysis. One such variable was HPV or HPV vaccine knowledge. Had this 
variable been collected for all survey years included in the analysis, the change in HPV or 
HPV vaccine awareness could have been assessed for the treatment or policy states.  
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Major Findings 
Despite these limitations, the dissertation filled several important gaps in the 
literature and produced the following findings:  
o The prevalence of infection from high-risk HPV types was higher among 
females aged 27  59 years in the South compared to their counterparts in 
the rest of the country. 
o  The prevalence infection with oncogenic HPV types was higher among 
females aged 27  59 years in the South compared to their counterparts in 
the rest of the country. 
o Having more than four lifetime sex partners was associated with HPV 
infections. 
o Women who were sexually active and unmarried had higher odds of HPV 
infections compared with those who were married.  
o Virginia’s HPV vaccine mandate for school-entry may not have resulted in 
a significant increase in HPV vaccination among adolescent females.  
o In Virginia, physician recommendation remained strongly associated with 
HPV vaccination in spite of the implementation of the mandate. 
o Louisiana’s HPV/HPV vaccinate awareness policy may not have led to a 
significant increase in HPV vaccination when compared with states 
without such a policy. 
o Physician recommendation was strongly associated with HPV vaccination 
in Louisiana in spite of the parental awareness policy.  
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Public Health and Policy Implications 
Despite the availability of cervical cancer screening in the United States, the 
South continues to experience cervical cancer disparities.  HPV infection from high-risk 
types are higher in the South among women aged 27 years and above. To reduce 
disparities in cervical cancer incidence and mortality, public health efforts to increase 
cervical cancer screening in the South must continue. We must not only strive to achieve 
Healthy People 2020’s projected screening goal of 93%, but we must also ensure that 
screening services are accessible to women who are least likely to be screened. 
Particularly among Southern women, cervical cancer screening services should be made 
accessible to those with less than high school education, those living at 200% or below 
the federal poverty level (National Institute of Health, 2015), and those living in rural 
areas (Doescher & Jackson, 2009). Additionally, the rates of HPV infection are relatively 
high among 14  26 year-old females, which highlights the importance of vaccinating pre-
teens against HPV.  
The policy impact evaluation component of the dissertation was intended to 
facilitate evidence-based HPV vaccination policy-making. The effectiveness of a health 
policy depends generally on sociocultural, political, and economic factors, among others. 
HPV vaccination policies are not exceptional. The public perception of a policy, which 
depends, in part, on the media coverage, may have a considerable influence on its 
acceptance. In the case of Virginia’s HPV vaccine mandate for school-entry, the media 
coverage was not consistent or generally positive. Additionally, parents perceived the 
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mandate as an infringement on their rights. Such an unfavorable environment likely 
reduced parental compliance to the mandate.   
HPV vaccine awareness policies did not receive negative media coverage. 
However, HPV vaccination awareness alone was insufficient to lead to HPV vaccination. 
There are several factors that create a chasm between parental HPV vaccine awareness 
and getting the adolescent vaccinated. These barriers include lack of transportation, out-
of-pocket cost, parental consent, safety concerns, and parental concerns that the vaccine 
will promote sexual promiscuity. Uniform and consistent HPV information should be 
delivered to parents in order for them to understand the reasons the vaccine is needed. 
Furthermore, HPV vaccine awareness prepares parents and adolescents for physician 
recommendation and to ask pertinent questions to healthcare providers. Therefore, HPV 
vaccine awareness policies should be encouraged.   
Physician recommendation remains the principal factor associated with HPV 
vaccination. As a result, policy-makers should consider policies that may increase 
physician recommendation. State should introduce bills to fund HPV education and best 
practices regarding vaccine recommendation for current and future physicians.  
Additionally, similar trainings should be funded for and provided to other medium-level 
healthcare providers such as nurse practitioners and physician assistants, particularly 
those practicing in areas with cervical cancer disparities.   
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Directions for Future Research 
The findings indicate a higher prevalence of HPV infection from high-risk types 
in the American South. Further studies are needed to help understand and eliminate 
barriers to cervical cancer screening in the South. We did not find evidence that 
Virginia’s vaccine mandate or Louisiana’s HPV education policy led to an increase in 
vaccination among females aged 13  17 years. However, it found a strong association 
between physician recommendation and vaccination. Despite these important findings, 
the research could not point out all the factors that could dilute the impact of Louisiana’s 
HPV vaccination awareness or Virginia’s HPV vaccine mandate for school-entry. 
Investigations focusing on parental views as well as physician’s views of state policies 
are needed to better understand the socio-cultural contexts in which these policies may be 
effective. Moreover, since physician recommendation is the factor most strongly 
associated with vaccination, efforts to encourage physician recommendation must 
continue along with research to better understand its facilitators.  Furthermore, additional 
studies should investigate the role of nurses and physician assistants in facilitating 
physician recommendation.    
The dissertation supplied evidence coherent with the higher rates of cervical 
cancer in the American South. Furthermore, it has evaluated the impact of a HPV 
awareness policy as well as a HPV vaccine mandate. Although findings of this research 
indicated a higher prevalence of high-risk oncogenic HPV types among Southern women 
aged 27  59, it could not elucidate the causes for the geographic disparities in HPV 
infection. Further research may be needed to understand whether causal factors for these 
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differences are modifiable.  Moreover, the research could not point out all the factors that 
hindered the effectiveness of Louisiana’s HPV vaccination awareness or Virginia’s 
mandate. Investigations focusing on parental views as well as physician’s views of their 
state policies are needed to better understand the socio-cultural contexts in which these 
policies may be effective.    
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